CINXE.COM

<!DOCTYPE html> <html id="doc" lang="en" class="page-article"> <head id="Head1">  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" /> <script> var SCM = SCM || {}; if (SCM.AMA && SCM.AMA.DataLayerAsync) { SCM.AMA.DataLayerAsync.push("arrSisAffinity", "", "array"); SCM.AMA.DataLayerAsync.push("SubStatus", "no", "string"); } var googletag = window.googletag || {}; googletag.cmd = googletag.cmd || []; if (typeof Storage !== "undefined") { var targetingParamStr = localStorage.getItem("bcDFPTargetingParams"); if (targetingParamStr) { var targetingParameters = JSON.parse(targetingParamStr); // set page-level targeting parameters jQuery.each(targetingParameters, function (index, param) { googletag.cmd.push(function () { window.googletag.pubads().setTargeting(param.key, param.value); }); }); } } if (!googletag.pubads) { (function () { var gads = document.createElement('script'); var useSSL = 'https:' == document.location.protocol; gads.src = (useSSL ? 'https:' : 'http:') + '//securepubads.g.doubleclick.net/tag/js/gpt.js'; gads.setAttribute("async", ""); gads.setAttribute("defer", ""); var node = document.getElementsByTagName('script')[0]; node.parentNode.insertBefore(gads, node); })(); var App = App || {}; App.Ads = App.Ads || {}; App.Ads.adPath = App.Ads.adPath || '/6479/' + 'ama.jamanetworkopen'; App.Ads.Mappings = App.Ads.Mappings || {}; App.Ads.slots = App.Ads.slots || []; App.Ads.fromGoogle = !('yes' === 'yes'); App.isCollection = App.isCollection || !!document.getElementsByClassName('pg_collection').length; googletag.cmd.push(function () { googletag.pubads() .setTargeting('environment', ['newjama']) .setTargeting('site', ['ama.jamanetworkopen']) .setTargeting('sect', ['scholarly']) .setTargeting('sub', ['no']) .setTargeting('device', ['Mozilla%2F4.0%20%28compatible%3B%20MSIE%207.0%3B%20Windows%20NT%206.0%3B%20SLCC1%3B%20.NET%20CLR%202.0.50727%3B%20.NET%20CLR%203.0.04506%3B%20.NET%20CLR%203.5.21022%3B%20.NET%20CLR%201.0.3705%3B%20.NET%20CLR%201.1.4322%29']) .setTargeting('usaphys', ['no']) .setTargeting('memberstat', ['no']) .setTargeting('pracset', ['']) .setTargeting('specialty', ['other']) .setTargeting('occupation', ['']) .setTargeting('useraffinity', ['']) .setTargeting('direct', ['yes']) .setTargeting('bot', ['']) .setTargeting('datacenter', ['no']) .setTargeting('selfMPA', ['']) .setTargeting('selfSpecialty', ['']); if (App.isCollection) { googletag.pubads().setTargeting('collection', ['']); } var testParam = getQueryVariable('test'); if (testParam) { googletag.pubads().setTargeting('test', [testParam]); } function getQueryVariable(variable) { var query = window.location.search.substring(1); var vars = query.split('&'); for (var i = 0; i < vars.length; i++) { var pair = vars[i].split('='); if (decodeURIComponent(pair[0]) == variable) { return decodeURIComponent(pair[1]); } } } googletag.pubads().disableInitialLoad(); googletag.enableServices(); }); } </script> <meta name="viewport" content="width=device-width, initial-scale=1" /><meta name="format-detection" content="telephone=no" /><link rel="shortcut icon" href="//cdn.jamanetwork.com/UI/app/img/favicons/jamanetworkopen/favicon.ico"> <link rel="icon" type="image/png" href="//cdn.jamanetwork.com/UI/app/img/favicons/jamanetworkopen/favicon-192x192.png" sizes="192x192"> <link rel="apple-touch-icon" sizes="180x180" href="//cdn.jamanetwork.com/UI/app/img/favicons/jamanetworkopen/apple-touch-icon-180x180.png"> <meta http-equiv="X-UA-Compatible" content="IE=Edge" /> <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/dist/app.min.css?v=638677764476993385"> <link href="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.css" type="text/css" rel="stylesheet" /> <meta property="og:title" content="Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies in Clinical Trials" /> <meta property="og:type" content="Article" /> <meta property="og:url" content="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760661" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f1.png?Expires=2147483647&Signature=X5F6~okZTWpil8XtkfyeYuHsbTGZdiCS8zwPxn0pzuuwP7AxJgouZuJqH6aHEndAUJzO6DUU97bYIe-tfNO7vyydFCFjJxpyBo66MQnxd8RDGcKk1whZ5PBYmzsUNM0s6kBTS0iV9KNJ77P8E~IEsUpPPmVvvibu3cbQgiSj4VGCrOShrf1XoiAyje7hxyMm~72EXGjBBC-h6VhArLq4BWx6~G6xOeB1fV-lukipKGaNjFb9TCJqfjPkGgVFmKDUUyisFcb9LH97QbyDwPgiaGRe9r0I10QvpHuKY41KfqZ~zwCEmoAhH9ZExkE6kTo7d~izK1q~S4-XBV4HqEGfFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f2.png?Expires=2147483647&Signature=JK81Kkm41iuT5RH3yGEeriD5qvre4LYW5w10EriprCErxeNscZ9JQmNWIRoDigPm2JO8LWYUJxVaA6iNaF7Uc--Gm7tsKTaPKNqWwjzSehNoi1NeSpZRNuaI8~esXXkSnnQDXR5NsO4F-V8-Mjq2LhOthFbpWrwf40CSEPrlWnMwhhr25HM1zPs1yd~oKevQUo0Rr~UnoPBs8lPJpBQgcBrqA1Eic0CKKhuhW0QDxLPc3j9vgaYYIzxtFkUReo3a9JclEeMKQ8l~vCWWhRe8Ig2cA-1GmEtR08WYLFAchB1~twrg1WnkruiZSfY9ufPdpmMY~UcRM~oh1EJFEtF0Xw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f3.png?Expires=2147483647&Signature=mtaJZaQ~~Hw1J-k0Sw1p3nhzD36ulf6VsOnCYXM0imIoUoEzc98EmCyPbx4nckMgFJbvLo6vJqFkTkMDDmXTAJJxmhALnsO3U8t512euikv8OmKmqNpUjl2Qz9qZ3aekSJy23MsIp19glnK7RO~4bp-kLLpucFUMzwftJ8-SLvXb8zYV0GGVLL1eybsINE5nWRIMo0r~CzrkBJETIDMP0UUnTMKaZzo8UgbVZkEGv0f5AKtWQA6Si-CBNxsFe0angy75SvM67KjWyFitX8vWol6gU1Z5BpJRM1RfD9mxfJ55yYM7jZPdstsWIcZQodRKGHUyOtw5GwbntSJpo2X00w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f4.png?Expires=2147483647&Signature=fKVpYp-~WK~n6y~naYXxHpNqsmEfsKibAGNnwlAkmGWxjh2085m853JnPLXv805pnM-HZW78pu0akTillM4xSrLQNLewMLe1DetXe2WG9mKpFkyV8U4dMp5nVxZca9J7N0G7LJA3p9tsqbcRBoD9X9CQxn4Es6e9vWORhcNeyVBQce1g1HxF~YBH04hnjHY7jgp~XZl9RYfnGGheBBVCRVxZrfxjvBg8u~XBt-bqeWSh6Gj18KOF9vA1oh6vtDYZ5m59nlHvS4Qt8YidTLDzoLouzQZo5f662rXFmm9stXPgd7Ph1-FAOodWIcwJFndKMc4xCKs~CxZvMIpskSt~Yw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f5.png?Expires=2147483647&Signature=yXj5xXWFSM2U7rQekONENdupjonRa-U8kZQnFWTS9iC3-5e2WnNmmGVgzo4E0PDKjhrneIukqbP4MyyT4LMQqVEHmoKlhMzmIarMtOjAMkI~79Q9JXPvmD3~wRi2cM0XJZKW-jVWY5t4pyFJHXFAe-gtWjHgtJDZxKOTocCCXJKvxtpXwazfFPvpZg4c0WodJIxxr6qMWXw9P6E2HpKkE6Xi~qFZmsQ~u4q2dMk2bmSWLmlcSwpx8AP1F1z7UXs0w1H~G43SDgUInY1-0S2~1LPe~dIG1ADtbCuOh~XgSk4Ln~iZjSlNQbCMze~skvA2JU59PoRj2iVzFnvd3~plSw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <meta property="og:description" content="This cross-sectional study uses data from clinical trials to identify optimal strategies for combining programmed cell death 1 (PD-1) checkpoint inhibitors with other cancer therapies for patients with cancer who do not respond to PD-1 inhibitor monotherapy." /> <meta property="fb:pages" content="87087958340" /> <meta property="fb:pages" content="122228711814384" /> <meta property="fb:pages" content="1648414928738217" /> <meta property="fb:pages" content="117506346528" /> <meta property="fb:pages" content="97538728726" /> <meta property="fb:pages" content="114116793520" /> <meta property="fb:pages" content="100679858757" /> <meta property="fb:pages" content="759822190741773" /> <meta property="fb:pages" content="100265333750" /> <meta property="fb:pages" content="234770525256" /> <meta property="fb:pages" content="98784919862" /> <meta property="fb:pages" content="120829458202" /> <meta property="fb:pages" content="124842870398" /> <meta property="fb:pages" content="110245330325636" /> <meta name="twitter:card" content="summary_large_image" /> <meta name="twitter:site" content="@JAMANetworkOpen" /> <meta name="twitter:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f1.png?Expires=2147483647&Signature=X5F6~okZTWpil8XtkfyeYuHsbTGZdiCS8zwPxn0pzuuwP7AxJgouZuJqH6aHEndAUJzO6DUU97bYIe-tfNO7vyydFCFjJxpyBo66MQnxd8RDGcKk1whZ5PBYmzsUNM0s6kBTS0iV9KNJ77P8E~IEsUpPPmVvvibu3cbQgiSj4VGCrOShrf1XoiAyje7hxyMm~72EXGjBBC-h6VhArLq4BWx6~G6xOeB1fV-lukipKGaNjFb9TCJqfjPkGgVFmKDUUyisFcb9LH97QbyDwPgiaGRe9r0I10QvpHuKY41KfqZ~zwCEmoAhH9ZExkE6kTo7d~izK1q~S4-XBV4HqEGfFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" /> <link rel="alternate" hreflang="es" href="https://es.jamanetwork.com/journals/jamanetworkopen/fullarticle/2760661" /> <link rel="alternate" hreflang="zh-Hans" href="https://zh.jamanetwork.com/journals/jamanetworkopen/fullarticle/2760661" /> <link rel="alternate" hreflang="en-us" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760661" /> <link rel="alternate" hreflang="x-default" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760661" /> <script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "Article", "headline": "Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials", "author": "Emmett V. Schmidt, MD, PhD", "url": "https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760661", "datePublished": "2020-02-12", "description": "This cross-sectional study uses data from clinical trials to identify optimal strategies for combining programmed cell death 1 (PD-1) checkpoint inhibitors with other cancer therapies for patients with cancer who do not respond to PD-1 inhibitor monotherapy.", "publisher": { "@type": "Organization", "name": "JAMA Network", "logo": { "@type": "ImageObject", "url": "//cdn.jamanetwork.com/UI/app/img/favicons/jamanetworkopen/favicon.ico" } }, "image": [ "https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f1.png?Expires=2147483647&Signature=X5F6~okZTWpil8XtkfyeYuHsbTGZdiCS8zwPxn0pzuuwP7AxJgouZuJqH6aHEndAUJzO6DUU97bYIe-tfNO7vyydFCFjJxpyBo66MQnxd8RDGcKk1whZ5PBYmzsUNM0s6kBTS0iV9KNJ77P8E~IEsUpPPmVvvibu3cbQgiSj4VGCrOShrf1XoiAyje7hxyMm~72EXGjBBC-h6VhArLq4BWx6~G6xOeB1fV-lukipKGaNjFb9TCJqfjPkGgVFmKDUUyisFcb9LH97QbyDwPgiaGRe9r0I10QvpHuKY41KfqZ~zwCEmoAhH9ZExkE6kTo7d~izK1q~S4-XBV4HqEGfFg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f2.png?Expires=2147483647&Signature=JK81Kkm41iuT5RH3yGEeriD5qvre4LYW5w10EriprCErxeNscZ9JQmNWIRoDigPm2JO8LWYUJxVaA6iNaF7Uc--Gm7tsKTaPKNqWwjzSehNoi1NeSpZRNuaI8~esXXkSnnQDXR5NsO4F-V8-Mjq2LhOthFbpWrwf40CSEPrlWnMwhhr25HM1zPs1yd~oKevQUo0Rr~UnoPBs8lPJpBQgcBrqA1Eic0CKKhuhW0QDxLPc3j9vgaYYIzxtFkUReo3a9JclEeMKQ8l~vCWWhRe8Ig2cA-1GmEtR08WYLFAchB1~twrg1WnkruiZSfY9ufPdpmMY~UcRM~oh1EJFEtF0Xw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f3.png?Expires=2147483647&Signature=mtaJZaQ~~Hw1J-k0Sw1p3nhzD36ulf6VsOnCYXM0imIoUoEzc98EmCyPbx4nckMgFJbvLo6vJqFkTkMDDmXTAJJxmhALnsO3U8t512euikv8OmKmqNpUjl2Qz9qZ3aekSJy23MsIp19glnK7RO~4bp-kLLpucFUMzwftJ8-SLvXb8zYV0GGVLL1eybsINE5nWRIMo0r~CzrkBJETIDMP0UUnTMKaZzo8UgbVZkEGv0f5AKtWQA6Si-CBNxsFe0angy75SvM67KjWyFitX8vWol6gU1Z5BpJRM1RfD9mxfJ55yYM7jZPdstsWIcZQodRKGHUyOtw5GwbntSJpo2X00w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f4.png?Expires=2147483647&Signature=fKVpYp-~WK~n6y~naYXxHpNqsmEfsKibAGNnwlAkmGWxjh2085m853JnPLXv805pnM-HZW78pu0akTillM4xSrLQNLewMLe1DetXe2WG9mKpFkyV8U4dMp5nVxZca9J7N0G7LJA3p9tsqbcRBoD9X9CQxn4Es6e9vWORhcNeyVBQce1g1HxF~YBH04hnjHY7jgp~XZl9RYfnGGheBBVCRVxZrfxjvBg8u~XBt-bqeWSh6Gj18KOF9vA1oh6vtDYZ5m59nlHvS4Qt8YidTLDzoLouzQZo5f662rXFmm9stXPgd7Ph1-FAOodWIcwJFndKMc4xCKs~CxZvMIpskSt~Yw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA", "https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f5.png?Expires=2147483647&Signature=yXj5xXWFSM2U7rQekONENdupjonRa-U8kZQnFWTS9iC3-5e2WnNmmGVgzo4E0PDKjhrneIukqbP4MyyT4LMQqVEHmoKlhMzmIarMtOjAMkI~79Q9JXPvmD3~wRi2cM0XJZKW-jVWY5t4pyFJHXFAe-gtWjHgtJDZxKOTocCCXJKvxtpXwazfFPvpZg4c0WodJIxxr6qMWXw9P6E2HpKkE6Xi~qFZmsQ~u4q2dMk2bmSWLmlcSwpx8AP1F1z7UXs0w1H~G43SDgUInY1-0S2~1LPe~dIG1ADtbCuOh~XgSk4Ln~iZjSlNQbCMze~skvA2JU59PoRj2iVzFnvd3~plSw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" ], "articleSection": [ "Introduction", "Methods", "Study Design, Participants, and Data Sources", "Variables", "Statistical Analysis", "Results", "Discussion", "Limitations", "Conclusions", "Article Information" ], "keyWords": "malignant neoplasms, chemotherapy regimen, immune checkpoint inhibitors, apoptosis, platinum, cancer therapy, neoplasm metastasis, frequency of responses" } </script> <meta name="citation_author" content="Emmett V. Schmidt" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_author" content="Michael J. Chisamore" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_author" content="Marya F. Chaney" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_author" content="Marie E. Maradeo" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_author" content="James Anderson" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_author" content="Gretchen A. Baltus" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_author" content="Elaine M. Pinheiro" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_author" content="Victor N. Uebele" /><meta name="citation_author_institution" content="Merck and Co, Inc, Kenilworth, New Jersey" /><meta name="citation_title" content="Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials" /><meta name="citation_firstpage" content="e1920833" /><meta name="citation_lastpage" content="e1920833" /><meta name="citation_doi" content="10.1001/jamanetworkopen.2019.20833" /><meta name="citation_keyword" content="cancer" /><meta name="citation_keyword" content="chemotherapy regimen" /><meta name="citation_keyword" content="immune checkpoint inhibitors" /><meta name="citation_keyword" content="apoptosis" /><meta name="citation_keyword" content="platinum" /><meta name="citation_keyword" content="cancer therapy" /><meta name="citation_keyword" content="neoplasm metastasis" /><meta name="citation_keyword" content="frequency of responses" /><meta name="citation_abstract" content="<h3>Importance</h3><p>Because cancer drugs given in combination have the potential for increased tumor-cell killing, finding the best combination partners for programmed cell death 1 (PD-1) checkpoint inhibitors could improve clinical outcomes for patients with cancer.</p><h3>Objective</h3><p>To identify optimal strategies for combining PD-1 immune checkpoint inhibitors with other cancer therapies.</p><h3>Design, Setting, and Participants</h3><p>This cross-sectional study compiled 319 results from 98 clinical trials testing PD-1 pathway inhibitors alone or in combination with other agents among 24 915 patients with metastatic cancer. All clinical trials had a primary completion date before September 16, 2018. Data analysis was conducted from November 2018 to August 2019.</p><h3>Exposures</h3><p>Patients with metastatic cancer were treated with PD-1 immune checkpoint inhibitors alone or with other cancer therapies.</p><h3>Main Outcomes and Measures</h3><p>Clinical activity was measured as objective response rates (ORRs). Combination measures included fold change from monotherapy to combination ORR, comparison of observed combination ORRs with estimated combination ORRs based on independent additivity, and a computational model to assess clinical synergy. To assess whether the ORRs of various combinations may be greater than the independent contribution of each agent, a Bliss independent activity model was used to analyze observed combination ORRs, and a<i>Z</i>score, measuring the difference between observed and calculated ORRs, was generated.</p><h3>Results</h3><p>In 319 results from 98 clinical trials among 24 915 patients, ORRs for monotherapy were compared with combination data by indication and line of therapy, demonstrating an increased ORR in 105 of 127 results (82.7%) where ORRs were available for both PD-1 pathway inhibitor monotherapy and combination therapy. A few combinations showed increases above the Bliss-estimated activity, possibly identifying limited clinical synergy. The mean (SD)<i>Z</i>score for all trials was 0.0430 (0.0243). The mean (SD)<i>Z</i>score was 0.0923 (0.0628) for platinum chemotherapy regimen combinations, 0.0547 (0.0821) for vascular endothelial growth factor or vascular endothelial growth factor receptor tyrosine kinase inhibitor combinations, 0.0893 (0.086) for indoleamine 2,3-dioxygenase inhibitor combinations, and 0.0558 (0.0849) for cytotoxic T-lymphocyte–associated protein 4 inhibitor combinations.</p><h3>Conclusions and Relevance</h3><p>In this cross-sectional study, most combination trials showed the expected benefit of combining 2 active anticancer agents, but few combination trials showed clinical synergy according to the Bliss independent activity model.</p>" /><meta name="citation_journal_title" content="JAMA Network Open" /><meta name="citation_journal_abbrev" content="JAMA Netw Open" /><meta name="citation_volume" content="3" /><meta name="citation_issue" content="2" /><meta name="citation_publication_date" content="2020/02/05" /><meta name="citation_publisher" content="American Medical Association" /><meta name="citation_reference" content="citation_title=Cancer immunotherapy using checkpoint blockade.; citation_author=Ribas A; citation_author=Wolchok JD; citation_journal_title=Science; citation_year=2018; citation_volume=359; citation_issue=6382; citation_pages=1350-1355; " /><meta name="citation_reference" content="citation_title=Combination immunotherapy: a road map.; citation_author=Ott PA; citation_author=Hodi FS; citation_author=Kaufman HL; citation_author=Wigginton JM; citation_author=Wolchok JD; citation_journal_title=J Immunother Cancer; citation_year=2017; citation_volume=5; citation_pages=16" /><meta name="citation_reference" content="citation_title=The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia.; citation_author=Frei E; citation_author=Karon M; citation_author=Levin RH; citation_journal_title=Blood; citation_year=1965; citation_volume=26; citation_issue=5; citation_pages=642-656; " /><meta name="citation_reference" content="citation_title=Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice.; citation_author=Law LW; citation_journal_title=Cancer Res; citation_year=1952; citation_volume=12; citation_issue=12; citation_pages=871-878; " /><meta name="citation_reference" content="citation_title=The James Ewing lecture: the relationship between tumor mass and resistance to chemotherapy–implications for surgical adjuvant treatment of cancer.; citation_author=DeVita VT; citation_journal_title=Cancer; citation_year=1983; citation_volume=51; citation_issue=7; citation_pages=1209-1220; " /><meta name="citation_reference" content="Center for Drug Evaluation and Research. Clinical trial endpoints for the approval of cancer drugs and biologics. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics. Accessed December 27, 2019. " /><meta name="citation_reference" content="citation_title=Analysis of drug combinations: current methodological landscape.; citation_author=Foucquier J; citation_author=Guedj M; citation_journal_title=Pharmacol Res Perspect; citation_year=2015; citation_volume=3; citation_issue=3; " /><meta name="citation_reference" content="citation_title=Consensus on concepts and terminology for combined-action assessment: The Saariselkä agreement.; citation_author=Greco W; citation_author=Unkelbach HD; citation_author=Pöch G; citation_author=Sühnel J; citation_author=Kundi M; citation_author=Bödeker W; citation_journal_title=Arch Complex Environ Stud; citation_year=1992; citation_volume=4; citation_pages=65-69; " /><meta name="citation_reference" content="citation_title=The toxicity of poisons applied jointly.; citation_author=Bliss CI; citation_journal_title=Ann Appl Biol; citation_year=1939; citation_volume=26; citation_issue=3; citation_pages=585-615; " /><meta name="citation_reference" content="citation_title=The search for synergy: a critical review from a response surface perspective.; citation_author=Greco WR; citation_author=Bravo G; citation_author=Parsons JC; citation_journal_title=Pharmacol Rev; citation_year=1995; citation_volume=47; citation_issue=2; citation_pages=331-385; " /><meta name="citation_reference" content="citation_title=Oncology meets immunology: the cancer-immunity cycle.; citation_author=Chen DS; citation_author=Mellman I; citation_journal_title=Immunity; citation_year=2013; citation_volume=39; citation_issue=1; citation_pages=1-10; " /><meta name="citation_reference" content="citation_title=Comprehensive analysis of the clinical immuno-oncology landscape.; citation_author=Tang J; citation_author=Shalabi A; citation_author=Hubbard-Lucey VM; citation_journal_title=Ann Oncol; citation_year=2018; citation_volume=29; citation_issue=1; citation_pages=84-91; " /><meta name="citation_reference" content="citation_title=Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy.; citation_author=Palmer AC; citation_author=Sorger PK; citation_journal_title=Cell; citation_year=2017; citation_volume=171; citation_issue=7; citation_pages=1678-1691.e13; " /><meta name="citation_reference" content="citation_title=Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.; citation_author=Gadgeel SM; citation_author=Stevenson J; citation_author=Langer CJ; citation_journal_title=J Clin Oncol; citation_year=2016; citation_volume=34; citation_issue=15; citation_pages=9016" /><meta name="citation_reference" content="citation_title=Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).; citation_author=Atkins MB; citation_author=Plimack ER; citation_author=Puzanov I; citation_journal_title=J Clin Oncol; citation_year=2018; citation_volume=36; citation_issue=6; citation_pages=579" /><meta name="citation_reference" content="citation_title=Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results.; citation_author=Lee C-H; citation_author=Makker V; citation_author=Rasco DW; citation_journal_title=J Clin Oncol; citation_year=2018; citation_volume=36; citation_issue=15; citation_pages=4560" /><meta name="citation_reference" content="citation_title=Trends in the global immuno-oncology landscape.; citation_author=Tang J; citation_author=Pearce L; citation_author=O’Donnell-Tormey J; citation_author=Hubbard-Lucey VM; citation_journal_title=Nat Rev Drug Discov; citation_year=2018; citation_volume=17; citation_issue=12; citation_pages=922" /><meta name="citation_reference" content="citation_title=Response rate as a regulatory end point in single-arm studies of advanced solid tumors.; citation_author=Oxnard GR; citation_author=Wilcox KH; citation_author=Gonen M; citation_author=Polotsky M; citation_author=Hirsch BR; citation_author=Schwartz LH; citation_journal_title=JAMA Oncol; citation_year=2016; citation_volume=2; citation_issue=6; citation_pages=772-779; " /><meta name="citation_reference" content="citation_title=Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.; citation_author=Goffin J; citation_author=Baral S; citation_author=Tu D; citation_author=Nomikos D; citation_author=Seymour L; citation_journal_title=Clin Cancer Res; citation_year=2005; citation_volume=11; citation_issue=16; citation_pages=5928-5934; " /><meta name="citation_reference" content="citation_title=Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs.; citation_author=Sekine I; citation_author=Yamamoto N; citation_author=Kunitoh H; citation_journal_title=Ann Oncol; citation_year=2002; citation_volume=13; citation_issue=8; citation_pages=1300-1306; " /><meta name="citation_reference" content="citation_title=Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study.; citation_author=Long GV; citation_author=Dummer R; citation_author=Hamid O; citation_journal_title=J Clin Oncol; citation_year=2018; citation_volume=36; citation_issue=15; citation_pages=108" /><meta name="citation_fulltext_world_readable" content="" /><meta name="citation_pdf_url" content="https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2760661/schmidt_2020_oi_190782.pdf" /> <meta name="citation_xml_url" content="https://datafeed.jamanetwork.com/journals/jamanetworkopen/xml/2760661" /> <title>Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials | Oncology | JAMA Network Open | JAMA Network</title> <meta name="description" content="This cross-sectional study uses data from clinical trials to identify optimal strategies for combining programmed cell death 1 (PD-1) checkpoint"> <link rel="canonical" href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2760661" /> <meta name="citation_fulltext_world_readable" /> <script src="//cdn.jamanetwork.com/UI/app/dist/head.min.js?v=638677764511843155"></script> <script src="https://r451.jamanetwork.com/script.js" defer></script> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_HeaderScript"> <meta class="SCM-SharedWidgets-AsyncHeaderAdLoader" data-url="/AMA/AdTag/AMA_AdTag_HeaderScript" data-params="{"parameters":{"siteName":"jamanetworkopen","siteId":214,"journalId":187,"adDisplay":0,"adSection":"scholarly","adPosition":"","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"> </div> </head> <body data-sitename="jamanetworkopen" class="pg_article " data-thm="jaman"> <script> var App = App || {}; App.suppressAds = App.suppressAds || !!document.getElementsByClassName('suppress-ads').length; App.suppressGtm = App.suppressGtm || !!document.getElementsByClassName('suppress-gtm').length; </script> <div id="ad-interstitial" class="ad-interstitial"> <script defer> googletag.cmd.push(function() { if (App.suppressAds) { return; } // Define a web interstitial ad slot. let interstitialSlot = googletag.defineOutOfPageSlot( App.Ads.adPath + '/scholarly', googletag.enums.OutOfPageFormat.INTERSTITIAL, ); if (interstitialSlot) { App.Ads.slots[13] = interstitialSlot; // Enable optional interstitial triggers and register the slot. interstitialSlot .setTargeting('pos', ['interstitial']) .addService(googletag.pubads()) .setConfig({ interstitial: { triggers: { navBar: true, unhideWindow: true, }, }, }); googletag.display(interstitialSlot); googletag.pubads().refresh([interstitialSlot], { changeCorrelator: false }); googletag.enableServices(); } }); </script> </div> <a class="accessible js-skip-to-navigation" href="#skip-to-navigation">[Skip to Navigation]</a> <noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-WNKSNP" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WNKSNP');</script> <span class="hide tagmanagervalue" data-attribute="productName" data-value="JAMA Network Open" data-type="string"></span> <form method="post" action="./2760661" id="webform" class="m0"> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="9FALB28tEGxdeSSlBuxAzLgI8GG0Uz/leLN4dpmf4Rwy3O/aYLTZZv7QH2UkPIUjNH/hSCN8ucYiqo9ZRzBRUUJ8Gfk=" /> </div> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="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" /> </div> <input id="hdnSiteID" type="hidden" value="214" /> <input id="hdnDomain" type="hidden" value=".jamanetwork.com" /> <section class="master-header"> <script type='text/javascript'> var App = App || {}; App.LoginUserInfo = { isInstLoggedIn: [0], currentSessionId: 'bmf3ziovklei3kg0hfzgaqsh' }; </script> <input name="ctl00$ctl00$BodyContent$Header$hfGlobalSearchSiteURL" type="hidden" id="hfGlobalSearchSiteURL" value="https://jamanetwork.com/" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsPaidUser" type="hidden" id="hfAppIsPaidUser" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsMember" type="hidden" id="hfAppIsMember" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppSubscribedTo" type="hidden" id="hfAppSubscribedTo" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsIndividual" type="hidden" id="hfAppIsIndividual" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppHasAccess" type="hidden" id="hfAppHasAccess" value="false" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsReferredFromGoogle" type="hidden" id="hfAppIsReferredFromGoogle" value="False" /> <input name="ctl00$ctl00$BodyContent$Header$hfSolrAutoSuggestMinimumCharactersLength" type="hidden" id="hfSolrAutoSuggestMinimumCharactersLength" value="2" /> <input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalName" type="hidden" id="hfSolrJournalName" value="JAMA Network Open" /> <input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalID" type="hidden" id="hfSolrJournalID" value="J187" /> <input name="ctl00$ctl00$BodyContent$Header$hfAppIsLucy" type="hidden" id="hfAppIsLucy" value="true" /> <div class="header-wrap"> <header class="header"> <div class="widget-GdprCookieBanner widget-instance-GdprCookieBanner"> <div class="gdpr-cookie-wrapper js-gdpr-banner"> <div class="gdpr-cookie-body"> Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our <a href="https://jamanetwork.com/pages/privacy-policy#cookies">Cookie Policy</a> <span class="pipe">|</span> <a href="javascript:;" class="js-gdpr-cookie-acceptLink at-acceptgdpr">Continue</a> </div> <input id="hdnDomain" type="hidden" value=".jamanetwork.com" /> <input id="hdnDomainGdpr" type="hidden" value=".jamanetwork.com" /> <input id="hdnClientIdGdpr" type="hidden" value="3" /> </div> </div> <div class="network-bar"> <a class="jama-network" href="/" title="JAMA Network Home"> <img alt="JAMA Network Home" class="title-image" width="443" height="52" src="//cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg"> </a> </div> <a class="nav-toggler" href="#nav"> <div class="nav-toggler-indicator"> <span class="indicator-stroke"></span> <span class="indicator-stroke"></span> <span class="indicator-stroke"></span> <span class="indicator-stroke"></span> </div> <div class="nav-toggler-site"> <span id="BodyContent_Header_siteFullNamenav" class="nav-toggler-microsite"><span class='network'>JAMA</span> Network Open</span> </div> </a> <nav id="nav" class="nav hide" > <div class="nav-journal-level sb-nav-journal-level"> <a href="/journals/jamanetworkopen" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_0" class="home">Home</a><a href="/journals/jamanetworkopen/currentissue" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_1" class="issues">Issues</a><a href="/journals/jamanetworkopen/featured-topics" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_2" class="specialties">Specialties</a><a href="/journals/jamanetworkopen/pages/for-authors" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_3" class="for-authors">For Authors</a> </div> <div class="nav-journals"> <div class="widget-SelfServeContent widget-instance-HamburgerPublicationMenu"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="HamburgerPublicationMenu" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .nav-journals {margin-bottom: 1em;} .nav-heading {color: #B9B9B9;border-bottom: 1px solid #242424;border-top: 1px solid #242424;font-size: 1.15em;font-weight: 400;margin: 0;padding: .7em .75em;text-transform: uppercase;} a.no-bullet:before {content:none !important;} .nav-heading {font-size: 1.15em;margin-bottom:0;padding-left: 38px;} .nav-journals a.theme-jama {background-color: #242424;border-bottom: 1px solid #fff;border-top: 1px solid #fff;color: #fff;font-size: 1.15em;margin-bottom: 8px;padding: 11px 0 9px 37px;} .nav-journals a.theme-jama::before {background: unset;content: "\e91b";display: none;font-family: ama_icons !important;font-size: 1.25em;line-height: 1;} .nav-journals a.theme-jama-network-open {border-bottom:0;} .nav .widget-instance-HamburgerPublicationMenu a {padding-left: 36px;} .fake-ribbon {border-left: 8px solid #ed0973;} .fake-ribbon a:before {content:none;} .nav .widget-instance-HamburgerPublicationMenu .fake-ribbon a {padding-left:30px;} </style> <div class="fake-ribbon"><a href="/journals/jamanetworkopen/pages/jama-network-open-editors-summary">Podcast</a></div> <h2 class="nav-heading">Journals</h2> <a href="/journals/jama" class="theme-jama">JAMA</a> <a href="/journals/jamanetworkopen" class="theme-jama-network-open">JAMA Network Open</a> <a href="/journals/jamacardiology" class="theme-jama-cardiology">JAMA Cardiology</a> <a href="/journals/jamadermatology" class="theme-jama-dermatology">JAMA Dermatology</a> <a href="/journals/jama-health-forum" class="theme-jama-health-forum">JAMA Health Forum</a> <a href="/journals/jamainternalmedicine" class="theme-jama-internal-medicine">JAMA Internal Medicine</a> <a href="/journals/jamaneurology" class="theme-jama-neurology">JAMA Neurology</a> <a href="/journals/jamaoncology" class="theme-jama-oncology">JAMA Oncology</a> <a href="/journals/jamaophthalmology" class="theme-jama-ophthalmology">JAMA Ophthalmology </a> <a href="/journals/jamaotolaryngology" class="theme-jama-otolaryngology-head-neck-surgery">JAMA Otolaryngology–Head & Neck Surgery</a> <a href="/journals/jamapediatrics" class="theme-jama-pediatrics">JAMA Pediatrics</a> <a href="/journals/jamapsychiatry" class="theme-jama-psychiatry">JAMA Psychiatry</a> <a href="/journals/jamasurgery" class="theme-jama-surgery">JAMA Surgery</a> <a href="/journals/archneurpsyc" class="theme-archives-of-neurology-psychiatry-1919-1959-">Archives of Neurology & Psychiatry (1919-1959)</a> </div> </div> </div> <div class="nav-network-other"> <a href="https://edhub.ama-assn.org/jn-learning" id="BodyContent_Header_rptOtherResources_aItemResourceList_0" class="is-b link-jn-learning-cme" target="_blank">JN Learning / CME</a><a href="https://store.jamanetwork.com" id="BodyContent_Header_rptOtherResources_aItemResourceList_1" class="is-b link-subscribe" target="_blank">Subscribe</a><a href="https://careers.jamanetwork.com/" id="BodyContent_Header_rptOtherResources_aItemResourceList_2" class="is-b link-jobs" target="_blank">Jobs</a><a href="https://jamanetwork.com/pages/resources-for-librarians" id="BodyContent_Header_rptOtherResources_aItemResourceList_3" class="is-b link-institutions-librarians">Institutions / Librarians</a><a href="https://jamanetwork.com/pages/reprints-and-permissions" id="BodyContent_Header_rptOtherResources_aItemResourceList_4" class="is-b link-reprints-permissions" rel="nofollow">Reprints & Permissions</a> </div> <div class="white text-xxs"> <div class="p05 ml4 mr3 mb1 mt10 flex hamburger-menu-legal"> <a href="/pages/conditions-of-use" class="p0" rel="nofollow">Terms of Use</a> <span class="pl1 pr1">| </span> <a href="/pages/privacy-policy" class="p0" rel="nofollow">Privacy Policy</a> <span class="pl1 pr1">| </span> <a href="/pages/accessibility-statement" class="p0" rel="nofollow">Accessibility Statement</a> </div> <div class="ta-c"> <span class="pb1">2024 American Medical Association. All Rights Reserved</span> </div> </div> </nav> <a class="toolbar-search-trigger is-b" data-mobile-tog-target=".site-search"></a> <div id="site-search" role="search" class="site-search"> <div class="site-search-bar"> <div role="search"> <select name="ctl00$ctl00$BodyContent$Header$ddlForSearch" id="BodyContent_Header_ddlForSearch" Name="dropDownList" class="cs-select cs-skin-border" title="Search Site Selector" role="options" aria-labelledby="searchLabel"> <option value="J*">Search All</option> <option value="3">JAMA</option> <option value="214">JAMA Network Open</option> <option value="192">JAMA Cardiology</option> <option value="12">JAMA Dermatology</option> <option value="261">JAMA Forum Archive</option> <option value="193">JAMA Health Forum</option> <option value="15">JAMA Internal Medicine</option> <option value="16">JAMA Neurology</option> <option value="159">JAMA Oncology</option> <option value="17">JAMA Ophthalmology</option> <option value="18">JAMA Otolaryngology–Head & Neck Surgery</option> <option value="19">JAMA Pediatrics</option> <option value="14">JAMA Psychiatry</option> <option value="20">JAMA Surgery</option> <option value="23">Archives of Neurology & Psychiatry</option> </select> </div> <div class="search-input-container"> <input type="search" name="textbox" autocomplete="off" role="textbox" id="search-term" aria-labelledby="searchLabel" class="search-term at-microsite-search-term" placeholder="Enter Search Term" maxlength="255" title="Enter Search Term"> <ul id="umbrellaSiteAutoCompleteResults" class="term-list hidden"></ul> <label style="display:none" for="umbrellaSiteSearchInputHint" id="searchLabel">Input Search Term</label> <input class="searchTerm search-input" name="textbox" role="textbox" type="text" id="umbrellaSiteSearchInputHint" aria-labelledby="searchLabel" title="Input Search Term" autocomplete="off"> </div>  <a name="button" role="button" class="search-button is-b js-search-button" alt="search button" href="/searchresults"></a> </div> </div> <div id="BodyContent_Header_GlobalSignIn_auth" class="auth"> <a class="auth--trigger is-b is-a" href="javascript:;"> <span id="BodyContent_Header_GlobalSignIn_spnUserFullName" class="user-full-name">Sign In</span> </a> <div class="auth--dropdown js-signIn-dropdown"> <div class="auth--option auth--ind"> <div id="BodyContent_Header_GlobalSignIn_divUserFullName" class="auth--ind-user"></div> <div id="BodyContent_Header_GlobalSignIn_divIndSignIn" class="auth--ind-auth"> <div class="auth--title">Individual Sign In</div> <a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661" id="BodyContent_Header_GlobalSignIn_oauthSignInLink" rel="nofollow" class="auth--ind-sign-in">Sign in</a><a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661" id="BodyContent_Header_GlobalSignIn_oauthSignUpLink" rel="nofollow" class="auth--ind-create">Create an Account</a> </div> </div> <div id="BodyContent_Header_GlobalSignIn_divInstSignIn" class="auth--option auth--inst"> <div class="auth--inst-auth"> <div class="auth--title">Access through your institution</div> <a href="/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661" id="BodyContent_Header_GlobalSignIn_institutionSignIn" rel="nofollow" class="auth--shib">Sign In</a> </div> </div> </div> </div> </header> </div> <div class="editors-choice-header"> </div> <div id="BodyContent_Header_divAds" class="header-ad-wrap sb-background-primary-dark"> <div class="leader-ad desktop-only"> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_LeaderboardAd"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_LeaderboardAd" data-params="{"parameters":{"siteName":"jamanetworkopen","siteId":214,"journalId":187,"adDisplay":1,"adSection":"scholarly","adPosition":"atf","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> </div>  </section> <section class="master-main"> <div class="social-share hide" data-share-journal="JAMANetworkOpen" data-share-title="Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies in Clinical Trials"></div> <div class="widget-UserContentAccessWrite widget-instance-AMA_LocalStorage_Article"> <div class="SCM-SharedWidgets-LocalStorage-UserContentAccessWrite" data-values='{"id":"2760661","type":"Article","date":"11/23/2024 1:37:57 PM"}'></div> </div> <div class="widget-ArticleToggleView widget-instance-AMA_ArticleToggleView"> <div class="widget-ArticleFullView widget-instance-AMA_ArticleFullView"> <script> (function () { var bodyElem = document.querySelector('body'); var className = 'split-screen'; if (bodyElem.classList) { bodyElem.classList.add(className); } else { el.className += ' ' + className; } })(); </script> <div id="resources-panel" class="resources-panel"> <span class="hide tagmanagervalue" data-attribute="template" data-value="splitscreen" data-type="string"></span> <div class="tab-nav"> <a class="tab-nav-trigger tab-nav-full-text tablet-down" href="#full-text-tab"> <i class="icon-full_text"><span class="sr-t">full text icon</span></i> <div class="tab-nav-tab-name">Full Text</div> </a> <a class="tab-nav-trigger tab-nav-contents target-tab-active" href="#contents-tab"> <i class="icon-contents"><span class="sr-t">contents icon</span></i> <div class="tab-nav-tab-name">Contents</div> </a> <a class="tab-nav-trigger tab-nav-figure-table" href="#figure-table-tab"> <i class="icon-figures"><span class="sr-t">figure icon</span></i> <div class="tab-nav-tab-name">Figures / <br> Tables</div> </a> <a class="tab-nav-trigger tab-nav-multimedia" href="#multimedia-tab"> <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i> <div class="tab-nav-tab-name">Multimedia</div> </a> <a class="tab-nav-trigger tab-nav-supplemental" href="#supplemental-tab"> <i class="icon-attach"><span class="sr-t">attach icon</span></i> <div class="tab-nav-tab-name">Supplemental <br> Content</div> </a> <a class="tab-nav-trigger tab-nav-references" href="#references-tab"> <i class="icon-references"><span class="sr-t">references icon</span></i> <div class="tab-nav-tab-name">References</div> </a> <a class="tab-nav-trigger tab-nav-related" href="#related-tab"> <i class="icon-related"><span class="sr-t">related icon</span></i> <div class="tab-nav-tab-name">Related</div> </a> <a class="tab-nav-trigger tab-nav-comments" href="#comments-tab"> <i class="icon-user-comments"><span class="sr-t">comments icon</span></i> <div class="tab-nav-tab-name">Comments</div> </a> </div> <div class="resource-tabs"> <div id="contents-tab" class="resource-tab js-resource-tab contents-tab tab-active"> <div class="contents-tab-contents"> <a id="pdf-link" href="/journals/jamanetworkopen/articlepdf/2760661/schmidt_2020_oi_190782.pdf" class="toolbar-tool toolbar-pdf al-link pdfaccess js-pdfaccess" data-article-id="2760661" data-article-url="/journals/jamanetworkopen/articlepdf/2760661/schmidt_2020_oi_190782.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span> </a> <div class="content-comment-bubble"> <a class="content-comment-link"> <span class="content-comment-text">Comment</span> </a> </div> <div class="widget-ArticleJumpLinks widget-instance-AMA_ArticleJumpLinks_Widget"> <a href="#top" class="section-jump-link contents-tab-jump-link top-of-article" data-tab-toggle=".tab-nav-full-text">Top of Article</a> <ul class="section-jump-links bullet ml2 pl1"> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583252" data-tab-toggle=".tab-nav-full-text">Key Points</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583253" data-tab-toggle=".tab-nav-full-text">Abstract</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583258" data-tab-toggle=".tab-nav-full-text">Introduction</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583264" data-tab-toggle=".tab-nav-full-text">Methods</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583279" data-tab-toggle=".tab-nav-full-text">Results</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583294" data-tab-toggle=".tab-nav-full-text">Discussion</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583304" data-tab-toggle=".tab-nav-full-text">Conclusions</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583306" data-tab-toggle=".tab-nav-full-text">Article Information</a></li> <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#238583307" data-tab-toggle=".tab-nav-full-text">References</a></li> </ul> </div> </div> <div class="contents-tab-ad"> <div id="split-screen-contab"></div> </div> </div> <div id="figure-table-tab" class="resource-tab js-resource-tab figure-table-tab need-jobs-ad"> <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Figures_Tab"> <div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 1. Plot of the Objective Response Rates (ORRs) for Various Programmed Cell Death 1 Pathway Inhibitors Tested as Monotherapies</div><a id="zoi190782f1" class="figure-table-anchor"></a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="zoi190782f1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f1.png?Expires=1735262389&Signature=svN7OAvL5FieBx7LV8D5Hu962l0iZy1f38aU8zj77KffzrOYIAx9ag6WwloFkRl2pa0F-a1EAmrdieiaoFd8VVA24Gw7noRNxdXgVflJnat25r1ZXHB37yT0CNdRFgx-iXCIHXfFmm9PRGvSDp~0VaM6~svao4d0jxenZg6WCqOgsE~bMJ28VpcpsFO4jkBTVBzoZHw2gJfmJaZADWh8g-MdZvhCei5s3KYuxLcfQxfasfHvC4XBlJN1iiK1Asw0C0gxaUv6HQV2Mx7legCtHhQ9z5CoMY1RgM5mFCmYcUCOmW5coY4nhYKn3y8e8foLddbxktjpkZ0SKpm12jKCOg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="zoi190782f1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f1.png?Expires=1735262389&Signature=svN7OAvL5FieBx7LV8D5Hu962l0iZy1f38aU8zj77KffzrOYIAx9ag6WwloFkRl2pa0F-a1EAmrdieiaoFd8VVA24Gw7noRNxdXgVflJnat25r1ZXHB37yT0CNdRFgx-iXCIHXfFmm9PRGvSDp~0VaM6~svao4d0jxenZg6WCqOgsE~bMJ28VpcpsFO4jkBTVBzoZHw2gJfmJaZADWh8g-MdZvhCei5s3KYuxLcfQxfasfHvC4XBlJN1iiK1Asw0C0gxaUv6HQV2Mx7legCtHhQ9z5CoMY1RgM5mFCmYcUCOmW5coY4nhYKn3y8e8foLddbxktjpkZ0SKpm12jKCOg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=238583283&ar=2760661&imagename=&siteId=214" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"></span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"></span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f1.png?Expires=1735262389&Signature=svN7OAvL5FieBx7LV8D5Hu962l0iZy1f38aU8zj77KffzrOYIAx9ag6WwloFkRl2pa0F-a1EAmrdieiaoFd8VVA24Gw7noRNxdXgVflJnat25r1ZXHB37yT0CNdRFgx-iXCIHXfFmm9PRGvSDp~0VaM6~svao4d0jxenZg6WCqOgsE~bMJ28VpcpsFO4jkBTVBzoZHw2gJfmJaZADWh8g-MdZvhCei5s3KYuxLcfQxfasfHvC4XBlJN1iiK1Asw0C0gxaUv6HQV2Mx7legCtHhQ9z5CoMY1RgM5mFCmYcUCOmW5coY4nhYKn3y8e8foLddbxktjpkZ0SKpm12jKCOg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="zoi190782f1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/m_zoi190782f1.png?Expires=1735262389&Signature=sRBSz04DVsXrYUKQMflFn~ar108yCSmLFAw5x1GUvo6Mwvk59Or3u1fGAqTc09VdEy18ZicH0bP00R71ui0lNJZCGsekQS7bwLrTRpxST9EtwVbbXPRPm93csuyb3X07aRaNruuFExbXqlDf3mFuulla2e4FWa8~vKENMD-JZFjyes9SqP9hnpaWcpF4q67lyI1TsEJe6LN-s3kN5acRH3Tx3SBNAW~cLpMq9CA2~P3P0XiFYumZHUpvlZRHGdE4tJAvrOdZ4zJ-~n3qBrog~acUJw59dXqWg6-IN2659FP~vVhk~cSlmPKkVBuiOxGqiiOotwVdJbPC6lEuVURzQQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Plot of the Objective Response Rates (ORRs) for Various Programmed Cell Death 1 Pathway Inhibitors Tested as Monotherapies" class="content-img lazy" path-from-xml="zoi190782f1" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">The ORRs shown were for any programmed cell death 1 pathway inhibitor where tested or for the mean of all those tested for a given indication and line of therapy. Various biomarkers and cut points were used in these trials; the details of each trial can be found in eTable 2 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>. BC indicates breast cancer; CLL, chronic lymphocytic leukemia; CRC, colorectal carcinoma; DLBCL, diffuse large B-cell lymphoma; ER, estrogen receptor; FL, follicular lymphoma; GBM, glioblastoma; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; MSI, microsatellite instable; MSI-H, microsatellite instable–high; MSS, microsatellite stable; NHL, non-Hodgkin lymphoma; NSCLC, non–small cell lung cancer; NPC, nasopharyngeal cancer; PMBCL, primary mediastinal B-cell lymphoma; RCC, renal cell carcinoma; rrPMBCL, relapsed or refractory primary mediastinal B-cell lymphoma; SCC, squamous cell carcinoma; SCLC, small cell lung cancer; STS, soft-tissue sarcoma; and TNBC, triple-negative breast cancer.</p></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 2. Descriptive Statistics Analyzing Fold Change From Monotherapy to Combination Therapies Using Programmed Cell Death 1 Pathway Checkpoint Inhibitors</div><a id="zoi190782f2" class="figure-table-anchor"></a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="zoi190782f2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f2.png?Expires=1735262389&Signature=rzFm5FoN4b0ImSgy1oPnKFpfIKVH52otmfAfaUSfB1IaGgoJo3i4X-EiHV7pddfl0NP1AilBK~frsvXhJte8wgel3zwNgfX9BHZsTbtqI0iiUtAQnbqZOpkHzYMZ-IJoTjZ3tWbKZ4veLCb1tivGvgviOLU2zwhFtW0Rni~h7BRdLQ7B6kfRJ1XNVQOpj6JdIvHgeslt2bTNIcuzooM6CwfoBQz8FfRbqXHyYp67fehDJcP0xebDtLXIg590CznTRFRKimYkOxN~E38fckZXx7KCLsdrz9lQDiP2gxYKjy98uf4jXq4i3s2uf~YuhZbR1gHZjdpybqZr4lahMq6cpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="zoi190782f2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f2.png?Expires=1735262389&Signature=rzFm5FoN4b0ImSgy1oPnKFpfIKVH52otmfAfaUSfB1IaGgoJo3i4X-EiHV7pddfl0NP1AilBK~frsvXhJte8wgel3zwNgfX9BHZsTbtqI0iiUtAQnbqZOpkHzYMZ-IJoTjZ3tWbKZ4veLCb1tivGvgviOLU2zwhFtW0Rni~h7BRdLQ7B6kfRJ1XNVQOpj6JdIvHgeslt2bTNIcuzooM6CwfoBQz8FfRbqXHyYp67fehDJcP0xebDtLXIg590CznTRFRKimYkOxN~E38fckZXx7KCLsdrz9lQDiP2gxYKjy98uf4jXq4i3s2uf~YuhZbR1gHZjdpybqZr4lahMq6cpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=238583285&ar=2760661&imagename=&siteId=214" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"></span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"></span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f2.png?Expires=1735262389&Signature=rzFm5FoN4b0ImSgy1oPnKFpfIKVH52otmfAfaUSfB1IaGgoJo3i4X-EiHV7pddfl0NP1AilBK~frsvXhJte8wgel3zwNgfX9BHZsTbtqI0iiUtAQnbqZOpkHzYMZ-IJoTjZ3tWbKZ4veLCb1tivGvgviOLU2zwhFtW0Rni~h7BRdLQ7B6kfRJ1XNVQOpj6JdIvHgeslt2bTNIcuzooM6CwfoBQz8FfRbqXHyYp67fehDJcP0xebDtLXIg590CznTRFRKimYkOxN~E38fckZXx7KCLsdrz9lQDiP2gxYKjy98uf4jXq4i3s2uf~YuhZbR1gHZjdpybqZr4lahMq6cpA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="zoi190782f2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/m_zoi190782f2.png?Expires=1735262389&Signature=ulgLRmVpsdLLPhQsCRdR3~914u5ukli9aqPRSfOL8d2EbLlJLcdZEH2MUlvaFiAmYwAKd-Vg6o6u-~mZd7-XEP3PTX2c77ncYKGdk~2zFW7LmmjJDay~Uid-5BNMU3eUEuKKSV6cbUcqd0yGP3y0Is7H6fU5nFDghHl81i2mAPuruzNMzVzqVNhPWSfRxCYWmKOLuwNLqBq0EGMLYKmLOovFew2TvQZVG6wiRUEWR3RacrLcsYvTC5egp3uplPgr9Hse764Oeq0UkmQM2Hyo0pEUZl3Mg6MLZlqUOFOhh~2rnZFhuL12rnBEdL3RmYg~2zw83sVqbSh53QeeltHh7Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Descriptive Statistics Analyzing Fold Change From Monotherapy to Combination Therapies Using Programmed Cell Death 1 Pathway Checkpoint Inhibitors" class="content-img lazy" path-from-xml="zoi190782f2" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">A, Combinations on the x-axis are identified in eTable 3 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>. Orthogonal combinations (ie, chemotherapies and targeted therapies) vs immune synergy combinations (ie, the tumor microenvironment [TME], adaptive immunity, and innate immunity) are shown.</p></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 3. Contribution of Bliss Independent Combination Outcomes to Combination Trial Response Rates</div><a id="zoi190782f3" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="zoi190782f3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f3.png?Expires=1735262389&Signature=Uoqdo364yew00Cj0A2QYz7nAcUaWnGmUVqvAPcLEY8JN1QoMvs-nZBqFnpu5v0bL88lWg~Uig6YVdchtPqJ7NpObySIu2iQMoNzKvkAgR9pn5AciPh7ppe-f0q9DrgLEtZeDTGEFd~9Opk-HWelEdgHMR-i0HBKMDb9TbQphfC3rxtAILMzkkyEOzOrd0wrtw5tPGIAj-qkofzC3Z3jBkXNwkyG2K2lDT9KbYdqzzhA-x-pxoplFgpEwSwAwnTtN2JULkKMfmt4amx09EKheeB1ECUbZeWJXD8SYxQYhx3d0Rs~TJAlVmbXjlDDZCTkZRdxboh-JOsKWzhGGaUuDWw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="zoi190782f3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f3.png?Expires=1735262389&Signature=Uoqdo364yew00Cj0A2QYz7nAcUaWnGmUVqvAPcLEY8JN1QoMvs-nZBqFnpu5v0bL88lWg~Uig6YVdchtPqJ7NpObySIu2iQMoNzKvkAgR9pn5AciPh7ppe-f0q9DrgLEtZeDTGEFd~9Opk-HWelEdgHMR-i0HBKMDb9TbQphfC3rxtAILMzkkyEOzOrd0wrtw5tPGIAj-qkofzC3Z3jBkXNwkyG2K2lDT9KbYdqzzhA-x-pxoplFgpEwSwAwnTtN2JULkKMfmt4amx09EKheeB1ECUbZeWJXD8SYxQYhx3d0Rs~TJAlVmbXjlDDZCTkZRdxboh-JOsKWzhGGaUuDWw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=238583288&ar=2760661&imagename=&siteId=214" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f3.png?Expires=1735262389&Signature=Uoqdo364yew00Cj0A2QYz7nAcUaWnGmUVqvAPcLEY8JN1QoMvs-nZBqFnpu5v0bL88lWg~Uig6YVdchtPqJ7NpObySIu2iQMoNzKvkAgR9pn5AciPh7ppe-f0q9DrgLEtZeDTGEFd~9Opk-HWelEdgHMR-i0HBKMDb9TbQphfC3rxtAILMzkkyEOzOrd0wrtw5tPGIAj-qkofzC3Z3jBkXNwkyG2K2lDT9KbYdqzzhA-x-pxoplFgpEwSwAwnTtN2JULkKMfmt4amx09EKheeB1ECUbZeWJXD8SYxQYhx3d0Rs~TJAlVmbXjlDDZCTkZRdxboh-JOsKWzhGGaUuDWw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="zoi190782f3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/m_zoi190782f3.png?Expires=1735262389&Signature=rM1-kf6blAeWrOEhFAEcU9PwWaf55DMwwPunG~YZCayeQfIH1xE8AbW3KvwCfNx43Yt55ClzQZi4CMdI-hqWmYVABLNGZtDPEHecgfQ8GsQxOmjz3xVhssGSJcp13KVdvpcIAXku4H9nEYONm74EUFlZhuzT1flP~mh1sL-b~fXt5~EqQ88UeoRndKvBVUbo6-9u7me2zzTHoLIRKRGwYKf9DMR86~KGJTarX-1XgWq2C5SCG9L4OVddJLM9iqkiEE2WL4moA7u~9K2d0FDA7aCjG1cF9GMbc49RphLgM7fsnSDzH~N3Lv7pfxLRKQaJezfe83xc-BADjZ9u80B18Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Contribution of Bliss Independent Combination Outcomes to Combination Trial Response Rates" class="content-img lazy" path-from-xml="zoi190782f3" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">A, The Bliss model posits that the combination of 2 agents with independent activities will be estimated by the following equation: Y<sub>ab,P</sub> = Y<sub>a</sub> + Y<sub>b</sub> – Y<sub>a</sub> × Y<sub>b</sub>, in which Y<sub>ab,P</sub> represents the estimated proportion of patients responding to agents in combination, Y<sub>a</sub> represents the observed proportion responding to agent or regimen 1, and Y<sub>b</sub> represents the observed proportion responding to agent or regimen 2. B, Z (yellow) is the difference between the observed objective response rate (ORR) for a combination and the estimated ORR from the Bliss equation. Z can be positive or negative. C, The regression plot (solid line) describes the association between the Bliss-estimated ORR based on independent contributions and the ORR of combinations determined in clinical trials. The dashed lines indicate 95% prediction intervals, and the dots represent individual trials. D, The histogram describes the frequency distribution of <i>Z</i> scores beyond the ORRs estimated by the Bliss model for combination efficacy.</p></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 4. Programmed Cell Death 1 Checkpoint Pathway Combination Regimens Activity With Estimated Combination Outcome</div><a id="zoi190782f4" class="figure-table-anchor"></a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="zoi190782f4" href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f4.png?Expires=1735262389&Signature=Qq~6lYK0dI2aE3XtvUP~~PcVb0VW9NEZ7fRC8u343TgOs9QZ5jzmVCvs~IS~hulWKiZeKILNPiEFX04yuZUlIejp-m~wZd3ZjzwA7uH-eJjAI0jxpmkJijS5vqsXyQM2g9AjFTO9rag-Ad~TR9jk8a37gaweSw8IA8~3iwGjFPjHZjTm7-u1cOIzEXDrOAzU-x9GbxKWq3GP78hCc7VSJFQj6puuxp5a7S6soVKemnWx3jHu6DKGY5f0wbbg7HET6R-9n-Qt4-akjkFVpOZ8-U0L-h18Zz6nmbT0d4TMvgeXDPm1P6O8cvdNw8GDETVS40-3xnJiT-aUFjXZ5VeEuQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="zoi190782f4" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f4.png?Expires=1735262389&Signature=Qq~6lYK0dI2aE3XtvUP~~PcVb0VW9NEZ7fRC8u343TgOs9QZ5jzmVCvs~IS~hulWKiZeKILNPiEFX04yuZUlIejp-m~wZd3ZjzwA7uH-eJjAI0jxpmkJijS5vqsXyQM2g9AjFTO9rag-Ad~TR9jk8a37gaweSw8IA8~3iwGjFPjHZjTm7-u1cOIzEXDrOAzU-x9GbxKWq3GP78hCc7VSJFQj6puuxp5a7S6soVKemnWx3jHu6DKGY5f0wbbg7HET6R-9n-Qt4-akjkFVpOZ8-U0L-h18Zz6nmbT0d4TMvgeXDPm1P6O8cvdNw8GDETVS40-3xnJiT-aUFjXZ5VeEuQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=238583291&ar=2760661&imagename=&siteId=214" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"></span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"></span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f4.png?Expires=1735262389&Signature=Qq~6lYK0dI2aE3XtvUP~~PcVb0VW9NEZ7fRC8u343TgOs9QZ5jzmVCvs~IS~hulWKiZeKILNPiEFX04yuZUlIejp-m~wZd3ZjzwA7uH-eJjAI0jxpmkJijS5vqsXyQM2g9AjFTO9rag-Ad~TR9jk8a37gaweSw8IA8~3iwGjFPjHZjTm7-u1cOIzEXDrOAzU-x9GbxKWq3GP78hCc7VSJFQj6puuxp5a7S6soVKemnWx3jHu6DKGY5f0wbbg7HET6R-9n-Qt4-akjkFVpOZ8-U0L-h18Zz6nmbT0d4TMvgeXDPm1P6O8cvdNw8GDETVS40-3xnJiT-aUFjXZ5VeEuQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="zoi190782f4" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/m_zoi190782f4.png?Expires=1735262389&Signature=1zX-Fu7e5-zFgDyFqqTcNoqOYP6I62~FVA1KjhYyqYUZutwOi5gYRTGD7QrvE5cmz6yWx8uFM08NhzU2dKEAFlFm7AHQP0NCTaf4PUKSWXSrQbfqooK-zb0JkKBI1yY5SfDGu8WzRfy9sZpT~Aqy27MaxvkU8tt~SvaQIP6FObDQGXQNus8JIY7xI633xqcEJVMGY~R49M6Ky9Fho8nvvBNqNd-ucZEGbsBYx3Rxv1MOaeVNWMme6p-JjSJb8v-rTlnPOhHYGdJCgyIMUw7Mho5fVARL0c8BptR8DATPUjNCRMyhnX16TP-Sai7W8sqZJFO2-Pjek4CzPv0hoMDxVg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Programmed Cell Death 1 Checkpoint Pathway Combination Regimens Activity With Estimated Combination Outcome" class="content-img lazy" path-from-xml="zoi190782f4" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">Trials on the x-axis are identified in eTable 4 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>. Orthogonal combinations (ie, chemotherapies and targeted therapies) vs immune synergy combinations (ie, the tumor microenvironment [TME], adaptive immunity, and innate immunity) are shown.</p></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 5. Combination Dynamics of Combinations</div><a id="zoi190782f5" class="figure-table-anchor"></a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="zoi190782f5" href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f5.png?Expires=1735262389&Signature=5FP1vfnE5mK84YTokT6jslxyKZpxTa5KMN3WFWOQIXJ2rDWxY1H0xgzFbJyRoV3TL8o~z8GTAAByVv644n7BwLLgT8iHZu9M4RTSOFUaA~IlBfxqjP36Gu8vF7FKNv1BGRJMlBLlpyM~TEAR5Di5SB02rPaxMDkweYM5vdn4S9xiFu~-XDKhBX22NSMKSCi4yx59NbHVDCw3BJjQ7pbS-ykN8nBepN1lcvGOwd~529lNhxOYxW3MjaW76-0FWFcM-Pn3CISHvYY1g0iRpKEMCBgA9OsRnDAnhRmnDn3LtAN-IKCfJW949O7c2qk~ep-DUl9cxiMPJXjuNglmfVsY6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="zoi190782f5" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f5.png?Expires=1735262389&Signature=5FP1vfnE5mK84YTokT6jslxyKZpxTa5KMN3WFWOQIXJ2rDWxY1H0xgzFbJyRoV3TL8o~z8GTAAByVv644n7BwLLgT8iHZu9M4RTSOFUaA~IlBfxqjP36Gu8vF7FKNv1BGRJMlBLlpyM~TEAR5Di5SB02rPaxMDkweYM5vdn4S9xiFu~-XDKhBX22NSMKSCi4yx59NbHVDCw3BJjQ7pbS-ykN8nBepN1lcvGOwd~529lNhxOYxW3MjaW76-0FWFcM-Pn3CISHvYY1g0iRpKEMCBgA9OsRnDAnhRmnDn3LtAN-IKCfJW949O7c2qk~ep-DUl9cxiMPJXjuNglmfVsY6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=238583293&ar=2760661&imagename=&siteId=214" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"></span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"></span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782f5.png?Expires=1735262389&Signature=5FP1vfnE5mK84YTokT6jslxyKZpxTa5KMN3WFWOQIXJ2rDWxY1H0xgzFbJyRoV3TL8o~z8GTAAByVv644n7BwLLgT8iHZu9M4RTSOFUaA~IlBfxqjP36Gu8vF7FKNv1BGRJMlBLlpyM~TEAR5Di5SB02rPaxMDkweYM5vdn4S9xiFu~-XDKhBX22NSMKSCi4yx59NbHVDCw3BJjQ7pbS-ykN8nBepN1lcvGOwd~529lNhxOYxW3MjaW76-0FWFcM-Pn3CISHvYY1g0iRpKEMCBgA9OsRnDAnhRmnDn3LtAN-IKCfJW949O7c2qk~ep-DUl9cxiMPJXjuNglmfVsY6Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="zoi190782f5" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/m_zoi190782f5.png?Expires=1735262389&Signature=UdOLxms1KY1St0gEfhcl12K~wOvZA5QQrMn4jNi8SbjLIe-xjLUH9CXSu9yM6OOcOHeY5oK99i3qur01ZMBIx3h9AbC8mBkwWShlKS3A1UtiDBRIHzBOVQy1Zu264brDuE-mq8yvS34SE18PvWZtEt-lFVJ7LGcv8BAhXGcHCXlOjzFbr9M6UW8oXOs~kM0549uo-l8fpjIa~ugcYcZFeC4WQPi1gjkG6H-wMSE5PGH28OhzwB04RfbXw7JIU2OazsomCk59ut4lp3HRXnVoRJ5HIteIGJl9P7ohFAn1eurrHqoRfYNcdS4JSHpXEatq4feLX9Yq-bTdzG7DHmZNWw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Combination Dynamics of Combinations" class="content-img lazy" path-from-xml="zoi190782f5" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">Columns indicate the observed objective response rate (ORR) for the combination therapies. Squares indicate the monotherapy ORRs for the identified programmed cell death 1 (PD-1) checkpoint inhibitors; triangles, the monotherapy ORR for the identified combination agent; and orange lines, the Bliss estimated ORR. Whiskers indicate SEs, which were not reported in all trials. The distance between the line and column represents the <i>Z</i> score, which can be positive or negative. The columns, squares, triangles, and orange lines all use the y-axis ORR scale. Individual trials are identified on the x-axis and in eTable 5 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>. CTLA-4 indicates cytotoxic T-lymphocyte–associated protein 4; IDO, indoleamine 2,3-dioxygenase; VEGF, vascular endothelial growth factor; and VEGFR, vascular endothelial growth factor receptor.</p></div></div> </div> </div> <div id="multimedia-tab" class="resource-tab js-resource-tab multimedia-tab need-jobs-ad"> </div> <div id="supplemental-tab" class="resource-tab js-resource-tab supplemental-tab need-jobs-ad"> <div class="widget-ArticleDataSupplements widget-instance-AMA_Data_Supplements_Tab"> <div class="supplement"> <a id="note-ZOI190782-1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jamanetworkopen/938350/zoi190782supp1_prod.pdf?Expires=1735393078&Signature=jZnypZFIdb7A6Co53hxv5p41sowk2oiQWF9KEK1a93D53OmkbESb-uRmurSqqIrCtmVkccWqYxVS3ngodN1r88ZVOfImJTcXwy7MONc-dFqo~zOaz-jb3hQUX8kCeNvF7keuxCCNsPx-pCjs90Vosr4lsAtg4DZZw0AyV~EoQ06VIZ0~GtREfErawhtT-t-gE4loR~MNdbVZiO-dft7LhXUbgv~87Hj4riUW04j4UmHK96Tdp4CSPZLUFhWO3q10BvD4ENAZeTx3sKb9shY4LzyrUGimy1nGYOYj~qlxsiuMTYLbWVO6ulqjj4R0UshYXd8B-k6~Sy4-yi8AelxMGw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="supplement-link supplement-download stats-supplement-download" rel="nofollow"> <div class="pdf supplement-type"></div> <div class="supplement-title"><span class="title-label">Supplement.</span><p class="para"><strong>eTable 1. </strong>Master Table of All Combination Data</p><p class="para"><strong>eTable 2. </strong>Monotherapy Objective Response Rates Used in Calculations of Increased Activity</p><p class="para"><strong>eTable 3. </strong>Details, References, and Calculated Fold Change for Randomized Clinical Trials Shown in Figure 2</p><p class="para"><strong>eTable 4. </strong>Details, References, Bliss Independent Additivity, and Clinical Synergy (Z) Calculations for Randomized Clinical Trials Shown in Figure 4</p><p class="para"><strong>eTable 5. </strong>Figure 5 X-Axis Labels With References</p><p class="para"><strong>eTable 6. </strong>Approved Combination Regimens Using PD-1 Pathway Inhibitors</p><p class="para"><strong>eReferences.</strong></p></div> </a> </div> </div> </div> <div id="references-tab" class="resource-tab js-resource-tab references-tab need-jobs-ad"> <div class="references-wrap"> <div class="widget-SectionDisplay widget-instance-AMA_References_Tab"> <div class="references"><div class="reference"><a class="reference-number" id="zoi190782r1">1.</a><div class="reference-content">Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. <i xmlns:helper="urn:XsltStringHelper"> Science</i>. 2018;359(6382):1350-1355. doi:<a href="http://dx.doi.org/10.1126/science.aar4060">10.1126/science.aar4060</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29567705" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cancer%20immunotherapy%20using%20checkpoint%20blockade.&author=A%20Ribas&author=JD%20Wolchok&publication_year=2018&journal=Science&volume=359&pages=1350-1355" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.aar4060" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.aar4060" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r2">2.</a><div class="reference-content">Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. <i xmlns:helper="urn:XsltStringHelper"> J Immunother Cancer</i>. 2017;5:16. doi:<a href="http://dx.doi.org/10.1186/s40425-017-0218-5">10.1186/s40425-017-0218-5</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/28239469" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Combination%20immunotherapy%3A%20a%20road%20map.&author=PA%20Ott&author=FS%20Hodi&author=HL%20Kaufman&author=JM%20Wigginton&author=JD%20Wolchok&publication_year=2017&journal=J%20Immunother%20Cancer&volume=5&pages=16" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s40425-017-0218-5" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s40425-017-0218-5" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r3">3.</a><div class="reference-content">Frei E III, Karon M, Levin RH, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. <i xmlns:helper="urn:XsltStringHelper"> Blood</i>. 1965;26(5):642-656. doi:<a href="http://dx.doi.org/10.1182/blood.V26.5.642.642">10.1182/blood.V26.5.642.642</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/5321112" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20effectiveness%20of%20combinations%20of%20antileukemic%20agents%20in%20inducing%20and%20maintaining%20remission%20in%20children%20with%20acute%20leukemia.&author=E%20Frei&author=M%20Karon&author=RH%20Levin&publication_year=1965&journal=Blood&volume=26&pages=642-656" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1182/blood.V26.5.642.642" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1182/blood.V26.5.642.642" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r4">4.</a><div class="reference-content">Law LW. Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. <i xmlns:helper="urn:XsltStringHelper"> Cancer Res</i>. 1952;12(12):871-878.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/13009674" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20combinations%20of%20antileukemic%20agents%20on%20an%20acute%20lymphocytic%20leukemia%20of%20mice.&author=LW%20Law&publication_year=1952&journal=Cancer%20Res&volume=12&pages=871-878" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r5">5.</a><div class="reference-content">DeVita VT Jr. The James Ewing lecture: the relationship between tumor mass and resistance to chemotherapy–implications for surgical adjuvant treatment of cancer. <i xmlns:helper="urn:XsltStringHelper"> Cancer</i>. 1983;51(7):1209-1220. doi:<a href="http://dx.doi.org/10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO;2-J">10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO;2-J</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/6825044" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20James%20Ewing%20lecture%3A%20the%20relationship%20between%20tumor%20mass%20and%20resistance%20to%20chemotherapy%E2%80%93implications%20for%20surgical%20adjuvant%20treatment%20of%20cancer.&author=VT%20DeVita&publication_year=1983&journal=Cancer&volume=51&pages=1209-1220" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/(ISSN)1097-0142" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/(ISSN)1097-0142" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r6">6.</a><div class="reference-content">Center for Drug Evaluation and Research. Clinical trial endpoints for the approval of cancer drugs and biologics. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics</a>. Accessed December 27, 2019.</div></div><div class="reference"><a class="reference-number" id="zoi190782r7">7.</a><div class="reference-content">Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. <i xmlns:helper="urn:XsltStringHelper"> Pharmacol Res Perspect</i>. 2015;3(3):e00149. doi:<a href="http://dx.doi.org/10.1002/prp2.149">10.1002/prp2.149</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/26171228" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Analysis%20of%20drug%20combinations%3A%20current%20methodological%20landscape.&author=J%20Foucquier&author=M%20Guedj&publication_year=2015&journal=Pharmacol%20Res%20Perspect&volume=3&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r8">8.</a><div class="reference-content">Greco W, Unkelbach HD, Pöch G, Sühnel J, Kundi M, Bödeker W. Consensus on concepts and terminology for combined-action assessment: The Saariselkä agreement. <i xmlns:helper="urn:XsltStringHelper"> Arch Complex Environ Stud</i>. 1992;4:65-69. <a href="http://www.xn--tyelmosaaminen-8hbb51a.fi/aces/Greco%20et%20al%20Aces%204(3)1992.pdf">http://www.xn--tyelmosaaminen-8hbb51a.fi/aces/Greco%20et%20al%20Aces%204(3)1992.pdf</a>. Accessed December 27, 2019.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Consensus%20on%20concepts%20and%20terminology%20for%20combined-action%20assessment%3A%20The%20Saariselk%C3%A4%20agreement.&author=W%20Greco&author=HD%20Unkelbach&author=G%20Pöch&author=J%20Sühnel&author=M%20Kundi&author=W%20Bödeker&publication_year=1992&journal=Arch%20Complex%20Environ%20Stud&volume=4&pages=65-69" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r9">9.</a><div class="reference-content">Bliss CI. The toxicity of poisons applied jointly. <i xmlns:helper="urn:XsltStringHelper"> Ann Appl Biol</i>. 1939;26(3):585-615. doi:<a href="http://dx.doi.org/10.1111/j.1744-7348.1939.tb06990.x">10.1111/j.1744-7348.1939.tb06990.x</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20toxicity%20of%20poisons%20applied%20jointly.&author=CI%20Bliss&publication_year=1939&journal=Ann%20Appl%20Biol&volume=26&pages=585-615" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/j.1744-7348.1939.tb06990.x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/j.1744-7348.1939.tb06990.x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r10">10.</a><div class="reference-content">Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. <i xmlns:helper="urn:XsltStringHelper"> Pharmacol Rev</i>. 1995;47(2):331-385.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7568331" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20search%20for%20synergy%3A%20a%20critical%20review%20from%20a%20response%20surface%20perspective.&author=WR%20Greco&author=G%20Bravo&author=JC%20Parsons&publication_year=1995&journal=Pharmacol%20Rev&volume=47&pages=331-385" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r11">11.</a><div class="reference-content">Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. <i xmlns:helper="urn:XsltStringHelper"> Immunity</i>. 2013;39(1):1-10. doi:<a href="http://dx.doi.org/10.1016/j.immuni.2013.07.012">10.1016/j.immuni.2013.07.012</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/23890059" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Oncology%20meets%20immunology%3A%20the%20cancer-immunity%20cycle.&author=DS%20Chen&author=I%20Mellman&publication_year=2013&journal=Immunity&volume=39&pages=1-10" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.immuni.2013.07.012" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.immuni.2013.07.012" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r12">12.</a><div class="reference-content">Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. <i xmlns:helper="urn:XsltStringHelper"> Ann Oncol</i>. 2018;29(1):84-91. doi:<a href="http://dx.doi.org/10.1093/annonc/mdx755">10.1093/annonc/mdx755</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29228097" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Comprehensive%20analysis%20of%20the%20clinical%20immuno-oncology%20landscape.&author=J%20Tang&author=A%20Shalabi&author=VM%20Hubbard-Lucey&publication_year=2018&journal=Ann%20Oncol&volume=29&pages=84-91" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/annonc/mdx755" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/annonc/mdx755" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r13">13.</a><div class="reference-content">Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. <i xmlns:helper="urn:XsltStringHelper"> Cell</i>. 2017;171(7):1678-1691.e13.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29245013" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Combination%20cancer%20therapy%20can%20confer%20benefit%20via%20patient-to-patient%20variability%20without%20drug%20additivity%20or%20synergy.&author=AC%20Palmer&author=PK%20Sorger&publication_year=2017&journal=Cell&volume=171&pages=1678-1691.e13" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.cell.2017.11.009" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.cell.2017.11.009" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r14">14.</a><div class="reference-content">Gadgeel SM, Stevenson J, Langer CJ, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2016;34(15)(Suppl):9016. doi:<a href="http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.9016">10.1200/JCO.2016.34.15_suppl.9016</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab%20%28pembro%29%20plus%20chemotherapy%20as%20front-line%20therapy%20for%20advanced%20NSCLC%3A%20KEYNOTE-021%20cohorts%20A-C.&author=SM%20Gadgeel&author=J%20Stevenson&author=CJ%20Langer&publication_year=2016&journal=J%20Clin%20Oncol&volume=34&pages=9016" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2016.34.15_suppl.9016" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2016.34.15_suppl.9016" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r15">15.</a><div class="reference-content">Atkins MB, Plimack ER, Puzanov I, et al. Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2018;36(6)(Suppl):579. doi:<a href="http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.579">10.1200/JCO.2018.36.6_suppl.579</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20efficacy%20of%20axitinib%20%28axi%29%20in%20combination%20with%20pembrolizumab%20%28pembro%29%20in%20patients%20%28pts%29%20with%20advanced%20renal%20cell%20cancer%20%28aRCC%29.&author=MB%20Atkins&author=ER%20Plimack&author=I%20Puzanov&publication_year=2018&journal=J%20Clin%20Oncol&volume=36&pages=579" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2018.36.6_suppl.579" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2018.36.6_suppl.579" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r16">16.</a><div class="reference-content">Lee C-H, Makker V, Rasco DW, et al. Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results. <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2018;36(15)(Suppl):4560. doi:<a href="http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.4560">10.1200/JCO.2018.36.15_suppl.4560</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Lenvatinib%20%2B%20pembrolizumab%20in%20patients%20with%20renal%20cell%20carcinoma%3A%20updated%20results.&author=C-H%20Lee&author=V%20Makker&author=DW%20Rasco&publication_year=2018&journal=J%20Clin%20Oncol&volume=36&pages=4560" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.4560" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2018.36.15_suppl.4560" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r17">17.</a><div class="reference-content">Tang J, Pearce L, O’Donnell-Tormey J, Hubbard-Lucey VM. Trends in the global immuno-oncology landscape. <i xmlns:helper="urn:XsltStringHelper"> Nat Rev Drug Discov</i>. 2018;17(12):922.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30361553" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Trends%20in%20the%20global%20immuno-oncology%20landscape.&author=J%20Tang&author=L%20Pearce&author=J%20O’Donnell-Tormey&author=VM%20Hubbard-Lucey&publication_year=2018&journal=Nat%20Rev%20Drug%20Discov&volume=17&pages=922" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/nrd.2018.202" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/nrd.2018.202" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r18">18.</a><div class="reference-content">Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH. Response rate as a regulatory end point in single-arm studies of advanced solid tumors. <i xmlns:helper="urn:XsltStringHelper"> JAMA Oncol</i>. 2016;2(6):772-779. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.6315">10.1001/jamaoncol.2015.6315</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/26914340" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Response%20rate%20as%20a%20regulatory%20end%20point%20in%20single-arm%20studies%20of%20advanced%20solid%20tumors.&author=GR%20Oxnard&author=KH%20Wilcox&author=M%20Gonen&author=M%20Polotsky&author=BR%20Hirsch&author=LH%20Schwartz&publication_year=2016&journal=JAMA%20Oncol&volume=2&pages=772-779" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jamaoncol.2015.6315" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jamaoncol.2015.6315" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r19">19.</a><div class="reference-content">Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. <i xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</i>. 2005;11(16):5928-5934. doi:<a href="http://dx.doi.org/10.1158/1078-0432.CCR-05-0130">10.1158/1078-0432.CCR-05-0130</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16115935" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Objective%20responses%20in%20patients%20with%20malignant%20melanoma%20or%20renal%20cell%20cancer%20in%20early%20clinical%20studies%20do%20not%20predict%20regulatory%20approval.&author=J%20Goffin&author=S%20Baral&author=D%20Tu&author=D%20Nomikos&author=L%20Seymour&publication_year=2005&journal=Clin%20Cancer%20Res&volume=11&pages=5928-5934" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-05-0130" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-05-0130" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r20">20.</a><div class="reference-content">Sekine I, Yamamoto N, Kunitoh H, et al. Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. <i xmlns:helper="urn:XsltStringHelper"> Ann Oncol</i>. 2002;13(8):1300-1306. doi:<a href="http://dx.doi.org/10.1093/annonc/mdf202">10.1093/annonc/mdf202</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12181255" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Relationship%20between%20objective%20responses%20in%20phase%20I%20trials%20and%20potential%20efficacy%20of%20non-specific%20cytotoxic%20investigational%20new%20drugs.&author=I%20Sekine&author=N%20Yamamoto&author=H%20Kunitoh&publication_year=2002&journal=Ann%20Oncol&volume=13&pages=1300-1306" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/annonc/mdf202" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/annonc/mdf202" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r21">21.</a><div class="reference-content">Long GV, Dummer R, Hamid O, et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2018;36(15)(Suppl):108. doi:<a href="http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.108">10.1200/JCO.2018.36.15_suppl.108</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Epacadostat%20%28E%29%20plus%20pembrolizumab%20%28P%29%20versus%20pembrolizumab%20alone%20in%20patients%20%28pts%29%20with%20unresectable%20or%20metastatic%20melanoma%3A%20results%20of%20the%20phase%203%20ECHO-301%2FKEYNOTE-252%20study.&author=GV%20Long&author=R%20Dummer&author=O%20Hamid&publication_year=2018&journal=J%20Clin%20Oncol&volume=36&pages=108" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.108" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2018.36.15_suppl.108" xmlns:helper="urn:XsltStringHelper"> </span></div></div></div> </div> </div> </div> <div id="related-tab" class="resource-tab js-resource-tab related-tab need-jobs-ad"> <div class="widget-ArticleLinks widget-instance-AMA_See_Also_Related_Content"> </div> <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links"> <div class="sm-linked-content"> <div class="sm-linked-content--item"> <a href="https://jamanetwork.com/channels/genomics/" target="_blank" class="sm-linked-content--link fw-b sb-tc"><i class="icon-url d-ib thm-col"></i>JAMA Genomics Website</a> </div> </div> </div> <div class="widget-RelatedTopics widget-instance-AMA_Related_Topics"> <div class="related-topics-block"> <h4 class="related-topics-heading topic-suggestions-heading sb-sc"> See More About </h4> <div class="related-topics topic-suggestions"> <a href="https://jamanetwork.com/collections/5801/oncology" id="item_Link" class="related-topic topic-suggestion no-wrap sb-anchor-light">Oncology</a> <a href="https://jamanetwork.com/collections/44041/genomics-and-precision-health" id="item_Link_1" class="related-topic topic-suggestion no-wrap sb-anchor-light">Genomics and Precision Health</a> <a href="https://jamanetwork.com/collections/5786/targeted-and-immune-therapy" id="item_Link_2" class="related-topic topic-suggestion no-wrap sb-anchor-light">Targeted and Immune Therapy</a> </div> </div> </div> <div class="ymal--footer"> <div class="widget-WidgetLoader widget-instance-AMA_PersonalizedContent_SplitScreenView_Footer"> <div class="SCM-SharedWidgets-AsyncWidgetLoader" data-url="/Personalization/PersonalizedContent/AMA_PersonalizedContent_SplitScreenView_Footer" data-params="{"parameters":{"resourceIdToExclude":2760661,"resourceTypeToExclude":3},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> <hr /> <div class="manage-interest"> <h4><a href="#" class="manage-interests-link-no-access thm-col-sec">Sign Up for Emails Based on Your Interests</a></h4> <div class="widget-ManageCollectionInterests widget-instance-ManageCollectionInterests_SplitScreen"> <div class="manage-interests-modal reveal-modal small modal" data-reveal> <div class="manage-interests--header"> <div class="widget-SelfServeContent widget-instance-AMA_ManageInterests_Header"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="AllSitesManageInterestsHeader" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <h4>Select Your Interests</h4> <p>Customize your JAMA Network experience by selecting one or more topics from the list below.</p> </div> </div> </div><div class="manage-interests--categories"> <ul class="category-list"> <li><span class="category-list-item " data-categoryid="46425">Academic Medicine</span></li> <li><span class="category-list-item " data-categoryid="5489">Acid Base, Electrolytes, Fluids</span></li> <li><span class="category-list-item " data-categoryid="5504">Allergy and Clinical Immunology</span></li> <li><span class="category-list-item " data-categoryid="46447">American Indian or Alaska Natives</span></li> <li><span class="category-list-item " data-categoryid="5510">Anesthesiology</span></li> <li><span class="category-list-item " data-categoryid="42143">Anticoagulation</span></li> <li><span class="category-list-item " data-categoryid="6261">Art and Images in Psychiatry</span></li> <li><span class="category-list-item " data-categoryid="42097">Assisted Reproduction</span></li> <li><span class="category-list-item " data-categoryid="42099">Bleeding and Transfusion</span></li> <li><span class="category-list-item " data-categoryid="5548">Cardiology</span></li> <li><span class="category-list-item " data-categoryid="44036">Caring for the Critically Ill Patient</span></li> <li><span class="category-list-item " data-categoryid="6255">Challenges in Clinical Electrocardiography</span></li> <li><span class="category-list-item " data-categoryid="46435">Climate and Health</span></li> <li><span class="category-list-item " data-categoryid="46448">Climate Change</span></li> <li><span class="category-list-item " data-categoryid="44038">Clinical Challenge</span></li> <li><span class="category-list-item " data-categoryid="44039">Clinical Implications of Basic Neuroscience</span></li> <li><span class="category-list-item " data-categoryid="5614">Clinical Pharmacy and Pharmacology</span></li> <li><span class="category-list-item " data-categoryid="46499">Coaching</span></li> <li><span class="category-list-item " data-categoryid="5575">Complementary and Alternative Medicine</span></li> <li><span class="category-list-item " data-categoryid="44040">Consensus Statements</span></li> <li><span class="category-list-item " data-categoryid="46099">Coronavirus (COVID-19)</span></li> <li><span class="category-list-item " data-categoryid="5584">Critical Care Medicine</span></li> <li><span class="category-list-item " data-categoryid="46325">Cultural Competency</span></li> <li><span class="category-list-item " data-categoryid="44019">Dental Medicine</span></li> <li><span class="category-list-item " data-categoryid="5598">Dermatology</span></li> <li><span class="category-list-item " data-categoryid="44011">Diabetes and Endocrinology</span></li> <li><span class="category-list-item " data-categoryid="46320">Diagnostic Test Interpretation</span></li> <li><span class="category-list-item " data-categoryid="46498">Digital Health</span></li> <li><span class="category-list-item " data-categoryid="42054">Drug Development</span></li> <li><span class="category-list-item " data-categoryid="5621">Emergency Medicine</span></li> <li><span class="category-list-item " data-categoryid="5819">End of Life, Hospice, Palliative Care</span></li> <li><span class="category-list-item " data-categoryid="42107">Environmental Health</span></li> <li><span class="category-list-item " data-categoryid="46387">Equity, Diversity, and Inclusion</span></li> <li><span class="category-list-item " data-categoryid="42108">Ethics</span></li> <li><span class="category-list-item " data-categoryid="5644">Facial Plastic Surgery</span></li> <li><span class="category-list-item " data-categoryid="44012">Gastroenterology and Hepatology</span></li> <li><span class="category-list-item " data-categoryid="5664">Genetics and Genomics</span></li> <li><span class="category-list-item " data-categoryid="44041">Genomics and Precision Health</span></li> <li><span class="category-list-item " data-categoryid="5668">Geriatrics</span></li> <li><span class="category-list-item " data-categoryid="5670">Global Health</span></li> <li><span class="category-list-item " data-categoryid="46427">Guide to Statistics and Methods</span></li> <li><span class="category-list-item " data-categoryid="5672">Guidelines</span></li> <li><span class="category-list-item " data-categoryid="5674">Hair Disorders</span></li> <li><span class="category-list-item " data-categoryid="42113">Health Care Delivery Models</span></li> <li><span class="category-list-item " data-categoryid="42114">Health Care Economics, Insurance, Payment</span></li> <li><span class="category-list-item " data-categoryid="42116">Health Care Quality</span></li> <li><span class="category-list-item " data-categoryid="5680">Health Care Reform</span></li> <li><span class="category-list-item " data-categoryid="5830">Health Care Safety</span></li> <li><span class="category-list-item " data-categoryid="5682">Health Care Workforce</span></li> <li><span class="category-list-item " data-categoryid="5679">Health Disparities</span></li> <li><span class="category-list-item " data-categoryid="46328">Health Inequities</span></li> <li><span class="category-list-item " data-categoryid="44020">Health Policy</span></li> <li><span class="category-list-item " data-categoryid="46451">Health Systems Science</span></li> <li><span class="category-list-item " data-categoryid="5688">Hematology</span></li> <li><span class="category-list-item " data-categoryid="5692">History of Medicine</span></li> <li><span class="category-list-item " data-categoryid="5514">Humanities</span></li> <li><span class="category-list-item " data-categoryid="5697">Hypertension</span></li> <li><span class="category-list-item " data-categoryid="44043">Images in Neurology</span></li> <li><span class="category-list-item " data-categoryid="45887">Implementation Science</span></li> <li><span class="category-list-item " data-categoryid="5702">Infectious Diseases</span></li> <li><span class="category-list-item " data-categoryid="44044">Innovations in Health Care Delivery</span></li> <li><span class="category-list-item " data-categoryid="46477">JAMA Forum</span></li> <li><span class="category-list-item " data-categoryid="44070">JAMA Infographic</span></li> <li><span class="category-list-item " data-categoryid="5716">Law and Medicine</span></li> <li><span class="category-list-item " data-categoryid="45308">Leading Change</span></li> <li><span class="category-list-item " data-categoryid="44045">Less is More</span></li> <li><span class="category-list-item " data-categoryid="46327">LGBTQIA Medicine</span></li> <li><span class="category-list-item " data-categoryid="5720">Lifestyle Behaviors</span></li> <li><span class="category-list-item " data-categoryid="45311">Medical Coding</span></li> <li><span class="category-list-item " data-categoryid="5738">Medical Devices and Equipment</span></li> <li><span class="category-list-item " data-categoryid="44023">Medical Education</span></li> <li><span class="category-list-item " data-categoryid="5739">Medical Education and Training</span></li> <li><span class="category-list-item " data-categoryid="5713">Medical Journals and Publishing</span></li> <li><span class="category-list-item " data-categoryid="5746">Melanoma</span></li> <li><span class="category-list-item " data-categoryid="5766">Narrative Medicine</span></li> <li><span class="category-list-item " data-categoryid="5769">Nephrology</span></li> <li><span class="category-list-item " data-categoryid="5777">Neurology</span></li> <li><span class="category-list-item " data-categoryid="44052">Neuroscience and Psychiatry</span></li> <li><span class="category-list-item " data-categoryid="44053">Notable Notes</span></li> <li><span class="category-list-item " data-categoryid="5787">Nursing</span></li> <li><span class="category-list-item " data-categoryid="5788">Nutrition</span></li> <li><span class="category-list-item " data-categoryid="44027">Nutrition, Obesity, Exercise</span></li> <li><span class="category-list-item " data-categoryid="5791">Obesity</span></li> <li><span class="category-list-item " data-categoryid="44013">Obstetrics and Gynecology</span></li> <li><span class="category-list-item " data-categoryid="5796">Occupational Health</span></li> <li><span class="category-list-item " data-categoryid="5801">Oncology</span></li> <li><span class="category-list-item " data-categoryid="5804">Ophthalmology</span></li> <li><span class="category-list-item " data-categoryid="5808">Orthopedics</span></li> <li><span class="category-list-item " data-categoryid="5811">Otolaryngology</span></li> <li><span class="category-list-item " data-categoryid="44028">Pain Medicine</span></li> <li><span class="category-list-item " data-categoryid="46446">Palliative Care</span></li> <li><span class="category-list-item " data-categoryid="44029">Pathology and Laboratory Medicine</span></li> <li><span class="category-list-item " data-categoryid="45306">Patient Care</span></li> <li><span class="category-list-item " data-categoryid="6258">Patient Information</span></li> <li><span class="category-list-item " data-categoryid="5843">Pediatrics</span></li> <li><span class="category-list-item " data-categoryid="44060">Performance Improvement</span></li> <li><span class="category-list-item " data-categoryid="45315">Performance Measures</span></li> <li><span class="category-list-item " data-categoryid="42050">Perioperative Care and Consultation</span></li> <li><span class="category-list-item " data-categoryid="42125">Pharmacoeconomics</span></li> <li><span class="category-list-item " data-categoryid="42126">Pharmacoepidemiology</span></li> <li><span class="category-list-item " data-categoryid="5851">Pharmacogenetics</span></li> <li><span class="category-list-item " data-categoryid="44030">Pharmacy and Clinical Pharmacology</span></li> <li><span class="category-list-item " data-categoryid="5856">Physical Medicine and Rehabilitation</span></li> <li><span class="category-list-item " data-categoryid="42059">Physical Therapy</span></li> <li><span class="category-list-item " data-categoryid="45313">Physician Leadership</span></li> <li><span class="category-list-item " data-categoryid="44061">Poetry</span></li> <li><span class="category-list-item " data-categoryid="45316">Population Health</span></li> <li><span class="category-list-item " data-categoryid="46445">Primary Care</span></li> <li><span class="category-list-item " data-categoryid="45309">Professional Well-being</span></li> <li><span class="category-list-item " data-categoryid="44064">Professionalism</span></li> <li><span class="category-list-item " data-categoryid="5871">Psychiatry and Behavioral Health</span></li> <li><span class="category-list-item " data-categoryid="42128">Public Health</span></li> <li><span class="category-list-item " data-categoryid="5877">Pulmonary Medicine</span></li> <li><span class="category-list-item " data-categoryid="42129">Radiology</span></li> <li><span class="category-list-item " data-categoryid="42058">Regulatory Agencies</span></li> <li><span class="category-list-item " data-categoryid="46443">Reproductive Health</span></li> <li><span class="category-list-item " data-categoryid="5916">Research, Methods, Statistics</span></li> <li><span class="category-list-item " data-categoryid="42142">Resuscitation</span></li> <li><span class="category-list-item " data-categoryid="5896">Rheumatology</span></li> <li><span class="category-list-item " data-categoryid="46326">Risk Management</span></li> <li><span class="category-list-item " data-categoryid="38802">Scientific Discovery and the Future of Medicine</span></li> <li><span class="category-list-item " data-categoryid="46495">Sexual Health</span></li> <li><span class="category-list-item " data-categoryid="5833">Shared Decision Making and Communication</span></li> <li><span class="category-list-item " data-categoryid="5912">Sleep Medicine</span></li> <li><span class="category-list-item " data-categoryid="5915">Sports Medicine</span></li> <li><span class="category-list-item " data-categoryid="5533">Stem Cell Transplantation</span></li> <li><span class="category-list-item " data-categoryid="5921">Substance Use and Addiction Medicine</span></li> <li><span class="category-list-item " data-categoryid="5923">Surgery</span></li> <li><span class="category-list-item " data-categoryid="44065">Surgical Innovation</span></li> <li><span class="category-list-item " data-categoryid="44066">Surgical Pearls</span></li> <li><span class="category-list-item " data-categoryid="44067">Teachable Moment</span></li> <li><span class="category-list-item " data-categoryid="44034">The Art of JAMA</span></li> <li><span class="category-list-item " data-categoryid="44037">The Arts and Medicine</span></li> <li><span class="category-list-item " data-categoryid="6257">The Rational Clinical Examination</span></li> <li><span class="category-list-item " data-categoryid="5936">Tobacco and e-Cigarettes</span></li> <li><span class="category-list-item " data-categoryid="5938">Toxicology</span></li> <li><span class="category-list-item " data-categoryid="46433">Translational Medicine</span></li> <li><span class="category-list-item " data-categoryid="42136">Trauma and Injury</span></li> <li><span class="category-list-item " data-categoryid="5942">Treatment Adherence</span></li> <li><span class="category-list-item " data-categoryid="46323">Ultrasonography</span></li> <li><span class="category-list-item " data-categoryid="5947">Urology</span></li> <li><span class="category-list-item " data-categoryid="44069">Users' Guide to the Medical Literature</span></li> <li><span class="category-list-item " data-categoryid="5950">Vaccination</span></li> <li><span class="category-list-item " data-categoryid="5955">Venous Thromboembolism</span></li> <li><span class="category-list-item " data-categoryid="45312">Veterans Health</span></li> <li><span class="category-list-item " data-categoryid="5957">Violence</span></li> <li><span class="category-list-item " data-categoryid="42139">Women's Health</span></li> <li><span class="category-list-item " data-categoryid="45307">Workflow and Process</span></li> <li><span class="category-list-item " data-categoryid="42140">Wound Care, Infection, Healing</span></li> </ul> </div> <div class="manage-interests--alert-signup"> <div class="widget-SelfServeContent widget-instance-AMA_ManageInterests Header"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="ManageInterestsAlertSignUpText" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <link rel="stylesheet" href="https://cdn.jamanetwork.com/data/CSSUploads/jn-selfserve-modals.css?versionId=57973" /> <h5 class="modal--subtitle modal-mobile-padding">Get the latest research based on your areas of interest.</h5>   </div> </div> <div class="alert-input"> <div class="weekly-alert"> <input role="checkbox" type="checkbox" name="Weekly Email" id="weeklyAlert" value=""/> <label aria-label="Weekly Email" for="weeklyAlert" class="alert-check-label">Weekly Email</label> </div> <div class="monthly-alert"> <input role="checkbox" type="checkbox" name="Monthly Email" id="monthlyAlert" value="" /> <label aria-label="Weekly Email" for="monthlyAlert" class="alert-check-label">Monthly Email</label> </div> </div> </div> <div class="manage-interests--save-preferences"> <div class="save-preferences-btn thm-bg "> <span class="save-preferences-btn-text fw-b">Save Preferences</span> </div> </div> <div class="manage-interests--privacy-terms"> <a class="manage-interests--privacy-terms-color" href="/pages/privacy-policy">Privacy Policy</a> | <a class="manage-interests--privacy-terms-color" href="/pages/terms-of-use">Terms of Use</a></div> <a class="close-reveal-modal icon-close"></a> </div> </div> </div> <h4 class="thm-col-sec" align="center"> Others Also Liked </h4> <div id="trendmd-suggestions"></div> </div> <div id="comments-tab" class="resource-tab js-resource-tab comments-tab js-comments-tab single-comment-view"> <div class="widget-UserComment widget-instance-AMA_SplitScreen_UserComment"> <div id="comment-wrapper"> <div class="comment-btn"> <a id="modal-opener" class="btn d-b mb1 sb-background-sc js-modal-opener" href="javascript:;">Comment</a> </div> </div> </div> <div class="widget-UserCommentBody widget-instance-AMA_UserCommentBody_SplitScreen"> </div> </div> </div> </div> <a id="skip-to-navigation" href="#" tabindex="-1"></a> <div id="content-panel" class="content-panel"> <a id="top"></a> <div id="full-text-tab" class="resource-tab js-resource-tab full-text-tab"> <div class="widget-ArticleLinks widget-instance-AMA_ErrataArticleLinks_FullText"> </div> <div class="widget-ArticleLinks widget-instance-AMA_ArticleLinks_ToErrata_FullText"> </div> <div class="widget-ArticleNavLinks widget-instance-AMA_ArticleNavLinks"> <a class="toc-link btn" href="https://jamanetwork.com/journals/jamanetworkopen/issue/3/2">This Issue</a> </div> <div class="article-metrics-wrapper" id="divArticleLevelMetrics"> <div class="widget-ArticleLevelMetrics widget-instance-AMA_ArticleMetrics"> <div class="artmet-condensed-wrap clearfix"> <div class="artmet-condensed-stats clearfix"> <div class="artmet-item artmet-views"> <span class="artmet-text sb-sc">Views</span> <span class="artmet-number sb-sc">13,742</span> </div> <div class="artmet-item artmet-citations"> <a class="artmet-citations-link" href="https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=silverchair&SrcAuth=WosAPI&KeyUT=WOS:000515613500003&DestLinkType=FullRecord&DestApp=WOS_CPL" target="_blank"> <span class="artmet-text">Citations</span> <span class="artmet-number">44</span> </a> </div> <div class="artmet-item artmet-altmetric"> <div class="widget-AltmetricLink widget-instance-AMAv2_ArticleLevelMetrics_AltmetricLinkSummary">  <div id="altmetricEmbedId" class='altmetric-embed' data-link-target="_blank" data-badge-type="text" data-hide-no-mentions="false" data-doi="10.1001/jamanetworkopen.2019.20833" ></div> </div> </div> </div> <div class="artmet-modal-trigger-wrap"> <a rel="nofollow" class="artmet-modal-trigger" data-article-id="2760661"><i class="icon-metrics"></i><span>View Metrics</span></a> </div> </div> </div> </div> <ul class="toolbar"> <li class="toolbar-pdf-wrap toolbar-tool-wrap"> <a id="pdf-link" href="/journals/jamanetworkopen/articlepdf/2760661/schmidt_2020_oi_190782.pdf" class="toolbar-tool toolbar-pdf al-link pdfaccess js-pdfaccess" data-article-id="2760661" data-article-url="/journals/jamanetworkopen/articlepdf/2760661/schmidt_2020_oi_190782.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span> </a> </li> <li class="toolbar-share-wrap toolbar-tool-wrap"> <div class="toolbar-tool"> <a class="st-custom-button addthis_button_twitter is-b toolbar-twitter toolbar-share" data-network="twitter" data-title="" data-url="" data-email-subject="" rel="nofollow" href="javascript:;"> <span class="share-text">X</span> </a> <a class="st-custom-button addthis_button_facebook is-b toolbar-facebook toolbar-share" data-network="facebook" data-title="" data-url="" data-email-subject="" rel="nofollow" href="javascript:;"> <span class="share-text">Facebook</span> </a> <a class="toolbar-share-more-link is-a" rel="nofollow"><span class="icon icon-carrot_down social-arrow"></span><span class="more-text-wrap">More</span></a> <div class="toolbar-share-more"> <a class="st-custom-button addthis_button_linkedin is-b toolbar-linkedin toolbar-share" data-network="linkedin" data-title="" data-url="" data-email-subject="" rel="nofollow" href="javascript:;"> <span class="share-text">LinkedIn</span> </a> </div> </div> </li> <li class="toolbar-citation-wrap toolbar-tool-wrap"> <div class="widget-ToolboxGetCitation widget-instance-AMA_Get_Citation"> <a class="toolbar-tool toolbar-citation is-b stats-citation" rel="nofollow" data-reveal-id="get-citation" data-reveal> <span class="toolbar-link-text">Cite</span> <span class="toolbar-link-text-extra">This</span> </a> <div id="get-citation" class="reveal-modal get-citation" data-reveal> <h3 class="get-citation-title">Citation</h3> <p class="get-citation-citation">Schmidt EV<span class='al-author-delim'>, </span>Chisamore MJ<span class='al-author-delim'>, </span>Chaney MF, et al. Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials. <em>JAMA Netw Open.</em> 2020;3(2):e1920833. doi:10.1001/jamanetworkopen.2019.20833</p> <h4 class="get-citation-download-heading">Manage citations:</h4> <div class="get-citation-types"> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=0">Ris (Zotero)</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=1">EndNote</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=2">BibTex</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=3">Medlars</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=0">ProCite</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=3">RefWorks</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=0">Reference Manager</a> <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2760661&resourceType=3&citationFormat=0">Mendeley</a> </div> <p class="get-citation-copyright">© 2024 </p> <a class="close-reveal-modal icon-close" rel="nofollow"></a> </div> </div> </li> <li class="toolbar-permissions-wrap toolbar-tool-wrap"> <div class="widget-ToolboxPermissions widget-instance-AMA_Get_Permissions"> <a href="/pages/cc-by-nc-nd-license-permissions" rel="nofollow" id="PermissionsLink" class="toolbar-tool toolbar-permissions is-b" target="_blank"><span class="toolbar-link-text">Permissions</span></a> </div> </li> </ul> <div class="widget-ArticleTopInfo widget-instance-AMA_ArticleTop_Info_Widget"> <div class="meta-access-type open-access is-b"></div> <span class="hide tagmanagervalue" data-attribute="articleId" data-value="2760661" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="arrArticleAuthor" data-value="Emmett%20V.%C2%A0Schmidt%2C%C2%A0MD%2C%20PhD,Michael%20J.%C2%A0Chisamore%2C%C2%A0PhD,Marya%20F.%C2%A0Chaney%2C%C2%A0PhD,Marie%20E.%C2%A0Maradeo%2C%C2%A0PhD,James%C2%A0Anderson%2C%C2%A0PhD,Gretchen%20A.%C2%A0Baltus%2C%C2%A0BA,Elaine%20M.%C2%A0Pinheiro%2C%C2%A0PhD,Victor%20N.%C2%A0Uebele%2C%C2%A0PhD" data-type="array"></span> <span class="hide tagmanagervalue" data-attribute="articleDOI" data-value="10.1001/jamanetworkopen.2019.20833" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="articleTitle" data-value="Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="type" data-value="Original Investigation" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="thematicLabel" data-value="Oncology" data-type="array"></span> <span class="hide tagmanagervalue" data-attribute="issueVolume" data-value="3" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="issueNo" data-value="2" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="publishDate" data-value="February 5, 2020" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="topics" data-value="Oncology, Genomics and Precision Health, Targeted and Immune Therapy" data-type="array"></span> <span class="hide tagmanagervalue" data-attribute="topicCode" data-value="5801, 44041, 5786" data-type="array"></span> <span class="hide tagmanagervalue" data-attribute="category" data-value="Research" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="journalClub" data-value="No" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="contentStatus" data-value="Open Access" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="articlePubState" data-value="Final" data-type="string"></span> <span class="hide tagmanagervalue" data-attribute="contentMedium" data-value="Article" data-type="string"></span> <div class="meta-article-type-wrap"> <div class="meta-article-type thm-col">Original Investigation </div> <div class="meta-super-class">Oncology</div> </div> <div class="meta-date"><span class="epub"><span class="month">February </span><span class="day">12, </span><span class="year">2020</span></span></div> <div class="meta-article-title-wrap"> <h1 class="meta-article-title ">Assessment of Clinical Activity of PD-1 Checkpoint Inhibitor Combination Therapies Reported in Clinical Trials</h1> </div> <div class="meta-authors"> <span class="meta-authors--limited"><span class="wi-fullname brand-fg"><a href="/searchresults?author=Emmett+V.+Schmidt&q=Emmett+V.+Schmidt" rel=nofollow target="_blank">Emmett V. Schmidt, MD, PhD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Michael+J.+Chisamore&q=Michael+J.+Chisamore" rel=nofollow target="_blank">Michael J. Chisamore, PhD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Marya+F.+Chaney&q=Marya+F.+Chaney" rel=nofollow target="_blank">Marya F. Chaney, PhD<sup>1</sup></a></span>; <a class="meta-authors--etal td-u stats-meta-authors--etal">et al</a></span> <span class="meta-authors--remaining"><span class="wi-fullname brand-fg"><a href="/searchresults?author=Marie+E.+Maradeo&q=Marie+E.+Maradeo" rel=nofollow target="_blank">Marie E. Maradeo, PhD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=James+Anderson&q=James+Anderson" rel=nofollow target="_blank">James Anderson, PhD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Gretchen+A.+Baltus&q=Gretchen+A.+Baltus" rel=nofollow target="_blank">Gretchen A. Baltus, BA<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Elaine+M.+Pinheiro&q=Elaine+M.+Pinheiro" rel=nofollow target="_blank">Elaine M. Pinheiro, PhD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Victor+N.+Uebele&q=Victor+N.+Uebele" rel=nofollow target="_blank">Victor N. Uebele, PhD<sup>1</sup></a></span></span> </div> <div class="meta-author"> <a class="meta-author-title is-b stats-meta-author-toggle" data-tog-target=".meta-author-content">Author Affiliations</a> <a class="meta-articleinfo-jumplink section-jump-link scroll-to stats-scroll-to-articleinfo" data-tab-toggle=".tab-nav-full-text" href="#238583306">Article Information</a> <div class="meta-author-content"> <ul class="meta-author-affiliations"> <li class="meta-author-affiliation"> <div class="meta-author-name"><sup>1</sup>Merck and Co, Inc, Kenilworth, New Jersey</div> </li> </ul> </div> </div> <div class="meta-citation-wrap"> <span class="meta-citation-journal-name">JAMA Netw Open. </span><span class="meta-citation"> 2020;3(2):e1920833. doi:10.1001/jamanetworkopen.2019.20833</span> </div> </div> <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links"> <div class="sm-linked-content"> <div class="sm-linked-content--item"> <a href="https://jamanetwork.com/channels/genomics/" target="_blank" class="sm-linked-content--link fw-b sb-tc"><i class="icon-url d-ib thm-col"></i>JAMA Genomics Website</a> </div> </div> </div> <div class="widget-LinkedContentToolbar widget-instance-AMA_LinkedContentToolbar"> <div class="linked-content-toolbar"> <div class="hidden js-search-open-multimedia-by-default" showContentByDefault="False"></div> <div class="linked-content-controls"> <a class="linked-content-trigger td-n stats-graphical-abstract" href="#graphical-abstract-tab"> <i class="icon-visual-abstract"><span class="sr-t">visual abstract icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Visual <div>Abstract</div></div> </a> <a class="linked-content-trigger td-n stats-editorial-comment" href="#editorial-comment-tab"> <i class="icon-document"><span class="sr-t">editorial comment icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Editorial <div>Comment</div></div> </a> <a class="linked-content-trigger td-n stats-related-articles" href="#related-articles-tab"> <i class="icon-related"><span class="sr-t">related articles icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Related <div>Articles</div></div> </a> <a class="linked-content-trigger td-n stats-author-interviews" href="#author-interviews-tab"> <i class="icon-author_interview"><span class="sr-t">author interview icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Interviews</div> </a> <a class="linked-content-trigger td-n stats-more-multimedia" href="#more-multimedia-tab"> <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Multimedia</div> </a> <a class="linked-content-trigger td-n stats-listen-to-this-article" href="#listen-to-this-article-tab"> <i class="icon-audio"><span class="sr-t">audio icon</span></i> <div class="trigger-text d-ib va-m ta-l fw-5">Listen to <div>this article</div></div> </a> </div> <div class="linked-content-tabs"> <div id="graphical-abstract-tab" class="linked-content-tab graphical-abstract-tab"> <div class="widget-SectionDisplay widget-instance-AMA_GraphicalAbstract_Tab"> </div> </div> <div id="editorial-comment-tab" class="linked-content-tab editorial-comment-tab"> <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_EditorialComments"> </div> </div> <div id="related-articles-tab" class="linked-content-tab related-article-tab"> <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedArticle"> </div> <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedEditorsChoices"> </div> </div> <div id="author-interviews-tab" class="linked-content-tab linked-author-interviews-tab"> <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_AuthorInterviews"> </div> </div> <div id="listen-to-this-article-tab" class="linked-content-tab linked-listen-to-this-article-tab"> <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_ListenToThisArticle"> </div> </div> <div id="more-multimedia-tab" class="linked-content-tab more-multimedia-tab"> </div> </div> </div> </div> <div class="widget-ArticleFulltext widget-instance-AMA_Article_FullText_Widget"> <div class="article-full-text" data-userHasAccess="True"> <a class="article-section-id-anchor" id="238583252"></a> <span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc ">Key Points</span><p><strong>Question</strong> <span>What therapies are best combined with programmed cell death 1 (PD-1) checkpoint inhibitors to improve outcomes for patients with cancer who do not respond to PD-1 pathway inhibitor monotherapy?</span></p><p><strong>Findings</strong> <span>This cross-sectional study of 98 clinical trials, which included 24 915 patients with metastatic cancer, compared objective response rates of PD-1 checkpoint immunotherapies used alone and in combination. Most combinations succeeded, given that the fold change from monotherapy ORR to combination ORR increased in 82.7% of trials. The highest observed Z score was for trials testing the combination of PD-1 checkpoint inhibitors and platinum-containing chemotherapy regimens.</span></p><p><strong>Meaning</strong> <span>In this study, higher combination ORRs were found for chemotherapies; however, all classes of cancer agents could be successfully combined with PD-1 checkpoint inhibitors.</span></p> <a class="article-section-id-anchor" id="238583253"></a> <div class="h3 cb section-type-abstract decorated-hed "> <div class="heading-text thm-col sb-sc"> Abstract </div> </div> <p><strong>Importance</strong> <span>Because cancer drugs given in combination have the potential for increased tumor-cell killing, finding the best combination partners for programmed cell death 1 (PD-1) checkpoint inhibitors could improve clinical outcomes for patients with cancer.</span></p><p><strong>Objective</strong> <span>To identify optimal strategies for combining PD-1 immune checkpoint inhibitors with other cancer therapies.</span></p><p><strong>Design, Setting, and Participants</strong> <span>This cross-sectional study compiled 319 results from 98 clinical trials testing PD-1 pathway inhibitors alone or in combination with other agents among 24 915 patients with metastatic cancer. All clinical trials had a primary completion date before September 16, 2018. Data analysis was conducted from November 2018 to August 2019.</span></p><p><strong>Exposures</strong> <span>Patients with metastatic cancer were treated with PD-1 immune checkpoint inhibitors alone or with other cancer therapies.</span></p><p><strong>Main Outcomes and Measures</strong> <span>Clinical activity was measured as objective response rates (ORRs). Combination measures included fold change from monotherapy to combination ORR, comparison of observed combination ORRs with estimated combination ORRs based on independent additivity, and a computational model to assess clinical synergy. To assess whether the ORRs of various combinations may be greater than the independent contribution of each agent, a Bliss independent activity model was used to analyze observed combination ORRs, and a <i>Z</i> score, measuring the difference between observed and calculated ORRs, was generated.</span></p><p><strong>Results</strong> <span>In 319 results from 98 clinical trials among 24 915 patients, ORRs for monotherapy were compared with combination data by indication and line of therapy, demonstrating an increased ORR in 105 of 127 results (82.7%) where ORRs were available for both PD-1 pathway inhibitor monotherapy and combination therapy. A few combinations showed increases above the Bliss-estimated activity, possibly identifying limited clinical synergy. The mean (SD) <i>Z</i> score for all trials was 0.0430 (0.0243). The mean (SD) <i>Z</i> score was 0.0923 (0.0628) for platinum chemotherapy regimen combinations, 0.0547 (0.0821) for vascular endothelial growth factor or vascular endothelial growth factor receptor tyrosine kinase inhibitor combinations, 0.0893 (0.086) for indoleamine 2,3-dioxygenase inhibitor combinations, and 0.0558 (0.0849) for cytotoxic T-lymphocyte–associated protein 4 inhibitor combinations.</span></p><p><strong>Conclusions and Relevance</strong> <span>In this cross-sectional study, most combination trials showed the expected benefit of combining 2 active anticancer agents, but few combination trials showed clinical synergy according to the Bliss independent activity model.</span></p> <div class="movable-ad-target bta"> </div> <a class="article-section-id-anchor" id="238583258"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Introduction </div> </div> <a class="article-section-id-anchor" id="238583259"></a> <p class="para">Advances in immunotherapy are changing treatment paradigms for most cancers.<sup><a href="#zoi190782r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> When given in combination, cancer drugs have the potential to increase tumor-cell killing. Therefore, following the success of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) agents as monotherapies, research is turning to identifying effective combinations.<sup><a href="#zoi190782r2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">2</a></sup> Historically, the rationale for combining therapies has been that using 2 effective drugs with independent mechanisms of action would decrease the likelihood that resistant cancer cells could develop,<sup><a href="#zoi190782r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup> a strategy that addresses clonal heterogeneity.<sup><a href="#zoi190782r4" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">4</a></sup> DeVita<sup><a href="#zoi190782r5" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">5</a></sup> and others have shown that agents active by any mechanism in shrinking tumors combine successfully. The activity of cancer treatments is defined by the US Food and Drug Administration (FDA) by using the overall response rate (ORR) in clinical trials, where the ORR is defined as the “proportion of patients with tumor size reduction of a predefined amount for a minimum time period.”<sup><a href="#zoi190782r6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup></p> <a class="article-section-id-anchor" id="238583260"></a> <p class="para">Clinicians have long sought to find combinations of drugs that might achieve <i>synergy</i>, defined as more than an additive effect.<sup><a href="#zoi190782r7" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">7</a></sup> This has been such a key aspiration across all medical fields that a consensus conference in Saariselkä, Finland, determined that a mathematical definition of synergy requires comparison with the Bliss independence model.<sup><a href="#zoi190782r8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> The Bliss model posits that the combination of 2 agents with independent activities will be estimated by the following equation<sup><a href="#zoi190782r9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup>: Y<sub>ab,P</sub> = Y<sub>a</sub> + Y<sub>b</sub> – Y<sub>a</sub> × Y<sub>b</sub>, in which Y<sub>ab,P</sub> represents the estimated proportion of patients responding to agents in combination, Y<sub>a</sub> represents the observed proportion responding to agent or regimen 1, and Y<sub>b</sub> represents the observed proportion responding to agent or regimen 2. This model for independent action is the consensus standard for evaluating independent additive contributions of drugs to combinations.<sup><a href="#zoi190782r10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup></p> <a class="article-section-id-anchor" id="238583261"></a> <p class="para">In contrast, coincident with rapid advances in our understanding of the immune system, more than 550 references to checkpoint inhibition in PubMed invoked synergy in the absence of mathematic testing. For example, combinations based on the cancer immunity cycle have been proposed to identify synergy.<sup><a href="#zoi190782r11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a></sup> This search for synergy differs from the historical approach to cancer therapies for 2 main reasons. First, immunologically targeted combination agents have similar, not independent, mechanisms of action. Second, the monotherapy activity of 1 combination partner is not strictly required, based on the premise that synergy will uncover anticancer activity that was unseen as monotherapy. We will refer to this approach to developing combinations as the search for <i>immunologic synergy</i>.</p> <a class="article-section-id-anchor" id="238583262"></a> <p class="para">Combinations based on both independent action and immunologic synergy can be found in the more than 3000 clinical trials involving immunotherapies.<sup><a href="#zoi190782r12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">12</a></sup> Optimal combinations could yield more than independently additive effects, which we are calling <i>clinical synergy</i>.<sup><a href="#zoi190782r10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup> It is not at all clear whether immunologic synergy can lead to clinical synergy. This association was tested by Palmer and Sorger,<sup><a href="#zoi190782r13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup> who evaluated data from the combination of ipilimumab and nivolumab in patients with melanoma to show that combination progression-free survival and combination best overall response curves were no greater than the sum expected from each individual agent, as estimated by independence. They concluded that this combination presented no evidence for clinical synergy.<sup><a href="#zoi190782r13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup> Thus, the claimed immunologic synergy for ipilimumab plus nivolumab did not result in clinical synergy.</p> <a class="article-section-id-anchor" id="238583263"></a> <p class="para">To enable a rigorous analysis of cancer therapy combination strategy, we compiled and systematically evaluated studies that reported ORRs for clinical combinations involving PD-1 pathway checkpoint inhibitors. We systematically reviewed clinical trials reporting ORRs for PD-1 pathway checkpoint combinations treating advanced metastatic cancers. We then compared the degree to which combination activity could be attributed to the independent activity of each agent vs mathematically greater activity that would be consistent with clinical synergy.</p> <a class="article-section-id-anchor" id="238583264"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Methods </div> </div> <a class="article-section-id-anchor" id="238583265"></a> <p class="para">Per the Office of Scientific and Technical Information Clearance at Merck and Co, this study did not require institutional review board approval because it did not involve direct experimentation among patients. All collected studies were reported on ClinicalTrials.gov and adhered to appropriate standards for ethical research. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (<a href="http://www.equator-network.org/reporting-guidelines/strobe/">STROBE</a>) reporting guideline.</p> <a class="article-section-id-anchor" id="238583266"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Study Design, Participants, and Data Sources </div> </div> <a class="article-section-id-anchor" id="238583267"></a> <p class="para">Clinical trials involving approved PD-1 or PD-L1 immune checkpoint inhibitors (ie, atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, or pembrolizumab) with results posted before September 16, 2018, were identified by a search at ClinicalTrials.gov. We assessed all trials listed as having a primary completion date before that date. We excluded trials as follows: (1) trials with 9 or fewer subjects, (2) terminated trials, (3) withdrawn trials, (4) trials in which combinations were not administered concurrently, (5) combination trials in biomarker-selected populations, (6) trials that included patients who had undergone prior PD-1 therapies, and (7) trials among patients with stage 1 to 3 diseases. Data entries were cross-checked by at least 2 of the audit team (E.V.S., M.J.C., M.F.C., and M.E.M) for the database.</p> <a class="article-section-id-anchor" id="238583268"></a> <p class="para">Additional clinical trials whose results were not yet posted at ClinicalTrials.gov were identified through a systematic review of abstracts presented at major oncology meetings (ie, American Society of Clinical Oncology, American Association for Cancer Research, Gastrointestinal Cancers Symposium, Genitourinary Cancers Symposium, American Society of Clinical Oncology–Society for Immunotherapy of Cancer Immuno-Oncology Symposium, American Society of Hematology, European Hematology Association, European Society for Medical Oncology, San Antonio Breast Cancer Symposium, Society of Gynecologic Oncology, Society for Immunotherapy of Cancer, Targeted Anticancer Therapies, and World Conference on Lung Cancer). Data from additional studies were identified in PubMed using the search terms <i>clinical trial</i>, <i>combination,</i> or <i>therapy</i> with PD-1 pathway inhibitor names. The cross-sectional study sample size was determined by these combined searches.</p> <a class="article-section-id-anchor" id="238583269"></a> <p class="para">Data were compiled in a tabular-formatted flat database (eTable 1 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>). Where results were available from both the literature and at ClinicalTrials.gov, we preferentially recorded literature-reported data. This database was compared with an annotated database (Beacon-Intelligence) to verify completeness. Taken together, these approaches identified all clinical trials involving PD-1 pathway inhibitors that reported ORRs at ClinicalTrials.gov, in articles, or at meeting presentations before the cutoff date.</p> <a class="article-section-id-anchor" id="238583270"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Variables </div> </div> <a class="article-section-id-anchor" id="238583271"></a> <p class="para">We identified ORRs for combination agents or combination regimens in meeting abstracts and/or by a literature search in PubMed. Each member of the audit team (E.V.S., M.J.C., M.F.C., and M.E.M.) independently identified combination agent and regimen data.</p> <a class="article-section-id-anchor" id="238583272"></a> <p class="para">Monotherapy ORRs were compiled and summarized by indication, line of therapy, and biomarker selection (eTable 2 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>). Where more than 1 PD-1 pathway inhibitor was tested in a line of therapy and indication, a consensus monotherapy ORR was calculated by a patient-number weighted mean of available monotherapy data. Where only 1 PD-1 pathway inhibitor was tested in a line of therapy and indication, it was recorded as such.</p> <a class="article-section-id-anchor" id="238583273"></a> <p class="para">Combination regimens were classified by mechanism as proposed in previous reviews of cancer immunotherapies.<sup><a href="#zoi190782r2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">2</a></sup><sup>,<a href="#zoi190782r12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">12</a></sup> Orthogonal combinations included radiotherapy, chemotherapy, and targeted therapies. Combinations based on immune synergy hypotheses included agents addressing innate immunity, adaptive immunity, and the tumor microenvironment. Classifications were assigned by consensus among 3 of us (E.V.S, G.A.B, and E.M.P).</p> <a class="article-section-id-anchor" id="238583274"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Statistical Analysis </div> </div> <a class="article-section-id-anchor" id="238583275"></a> <p class="para">The fold change from monotherapy to combination activity was calculated in the database by division when both values were available. Individual values were plotted in a column plot using Excel Office 365 (Microsoft Corp). Histograms assessing the aggregate data, together with calculation of normal curve parameters, was performed in Sigmaplot version 14.0 (Systat Software).</p> <a class="article-section-id-anchor" id="238583276"></a> <p class="para">A calculated combination ORR based on the Bliss independent activity model<sup><a href="#zoi190782r9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> for each combination was recorded as Y<sub>ab,P</sub> = Y<sub>a</sub> + Y<sub>b </sub>− Y<sub>a</sub> × Y<sub>b</sub>, in which Y<sub>ab,P</sub> indicates the estimated proportion of patients responding to agents in combination, Y<sub>a</sub> indicates the observed proportion responding to agent or regimen 1, and Y<sub>b</sub> indicates the observed proportion responding to agent or regimen 2.</p> <a class="article-section-id-anchor" id="238583277"></a> <p class="para">Observed ORRs were compared with Bliss-estimated ORRs using a linear regression plot in Prism version 8 (GraphPad), together with best fit calculations. The difference between the observed ORR and the Bliss-estimated ORR was calculated as a measure of clinical synergy using the following equation: <i>Z</i> = ORR − (Y<sub>a</sub> + Y<sub>b</sub> − Y<sub>a</sub> × Y<sub>b</sub>), in which the <i>Z</i> score was defined as the difference between the observed ORR for a combination and the estimated combination ORR according to the Bliss equation. Because the <i>Z</i> score measures deviation from additivity, it constitutes a measure of clinical synergy. Individual values were plotted in a column plot using Excel Office 365 (Microsoft Corp). Histograms assessing the aggregate data as well as descriptive statistics were performed in Sigmaplot (Systat Software).</p> <a class="article-section-id-anchor" id="238583278"></a> <p class="para">For platinum chemotherapies, vascular endothelial growth factor or vascular endothelial growth factor receptor (VEGF/R) inhibitors, indoleamine 2,3-dioxygenase (IDO) inhibitors, and cytotoxic T-lymphocyte–associated protein 4 (CTLA-4) inhibitors, all measures were determined for individual combinations and plotted using Sigmaplot (Systat Software). No tests of statistical significance were conducted, and therefore, no prespecified level of statistical significance was set.</p> <a class="article-section-id-anchor" id="238583279"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Results </div> </div> <a class="article-section-id-anchor" id="238583280"></a> <p class="para">We identified 98 trials, which included 24 915 patients with metastatic cancer, involving PD-1 or PD-L1 inhibitors for inclusion in our cross-sectional study. We first evaluated ClinicalTrials.gov for trials with a primary completion date before September 16, 2018, and identified 111 trials. Of these, 70 (63.1%) had accompanying results on ClinicalTrials.gov, and of those, 54 (77.1%) also reported data in an article or at a scientific congress. A search of publications and scientific congress abstracts yielded an additional 28 trials reporting ORRs.</p> <a class="article-section-id-anchor" id="238583281"></a> <p class="para">A total of 319 unique trial results were identified within these 98 trials, which were compiled in a master file of results for PD-1 pathway inhibitors (eTable 1 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>). Clinical activity was assessed as the ORR for each indication and line of therapy.</p> <a class="article-section-id-anchor" id="238583282"></a> <p class="para">Cancer drugs are generally developed through a sequence of tests starting in late-line therapies, among patients with no available treatment options. These are then advanced in line of therapy as their potential advantages over current standards of care are established. Consequently, monotherapy responses as well as combination responses to PD-1 and PD-L1 therapies were considered by indication and line of therapy (<a href="#zoi190782f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>). <a href="#zoi190782f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a> shows monotherapy ORRs for 46 indications, categorized by line of therapy and enrichment for expression of PD-L1.</p> <a class="article-section-id-anchor" id="238583284"></a> <p class="para">To assess potential combination benefit, the fold change from monotherapy response to combination therapy response was determined by dividing the ORR of combination therapy by the ORR of monotherapy using data from the same indication and line of therapy in biomarker-unselected populations (<a href="#zoi190782f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>A; eTable 3 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>). To compare combination results for orthogonal combinations (ie, chemotherapy and targeted therapies) with combinations chosen for potential immune synergy (ie, adaptive immunity, innate immunity, and the tumor microenvironment), results were plotted according to combination-regimen classes.</p> <a class="article-section-id-anchor" id="238583286"></a> <p class="para">A frequency plot of fold change data is shown for the total combination data set in <a href="#zoi190782f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>B, comparing combination therapy with PD-1 monotherapy. This plot shows a skewed normal distribution, with a mean (SD) fold increase of 2.06 (0.33) from monotherapy to combination therapy. The median fold change was 1.72 (95% CI, 1.45-1.97), and 105 of 127 results (82.7%) had a fold change greater than 1.0. A frequency plot of fold change data is shown for the total combination data set in <a href="#zoi190782f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>C, comparing the ORRs of combination therapies with those of the combining agents or regimens (eg, IDO inhibitors). The fold change in activity from combination regimen to combination therapy also followed a skewed normal distribution with a mean (SD) fold increase of 2.40 (0.35). The median fold change was 1.82 (95% CI, 1.52-2.18), and 81 of 95 results (85.3%) where ORRs were available for the combining regimen as monotherapy and combination therapy had a fold change greater than 1.0.</p> <a class="article-section-id-anchor" id="238583287"></a> <p class="para">The Bliss independent action model<sup><a href="#zoi190782r9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> is shown diagrammatically in <a href="#zoi190782f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>A and B. Using the Bliss independent action model, we calculated the predicted ORR for the 100 trials (90.1%) in which the ORRs for PD-1 pathway monotherapy and the combination agent or regimen were known. A regression plot comparing the actual observed ORR with the Bliss predicted ORR is shown in <a href="#zoi190782f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>C. The slope of the nonlinear regression was 1.073 (95% CI, 1.00-1.14; <i>R</i><sup>2</sup> = 0.675).</p> <a class="article-section-id-anchor" id="238583289"></a> <p class="para">Differences between observed ORRs and Bliss-estimated ORRs were calculated and shown as a frequency plot (<a href="#zoi190782f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>D). The plot fits a normal distribution (Shapiro-Wilk <i>P</i> = .83). The mean <i>Z</i> score contribution was 0.043 (95% CI, 0.019-0.67). Because this calculation measures additional activity, greater than estimated additive independent contributions, it offers a measure of clinical synergy.</p> <a class="article-section-id-anchor" id="238583290"></a> <p class="para">To compare orthogonal combinations (ie, chemotherapy and targeted therapies) with immune synergy combinations (ie, the tumor microenvironment, adaptive immunity, and innate immunity), the <i>Z</i> score was plotted as a measure of clinical synergy for all combinations in which the monotherapy ORR for the PD-1 checkpoint inhibitor and the combination regimen components were available (<a href="#zoi190782f4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 4</a>; eTable 4 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>). The mean <i>Z</i> score as a measure of clinical synergy for the therapeutic categories was 0.0763 (95% CI, 0.0242 to 0.1284) for chemotherapies, 0.0249 (95% CI, −0.0147 to 0.0645) for targeted therapies, 0.0755 (95% CI, −0.0076 to 0.1596) for tumor microenvironment therapies, 0.0232 (95% CI, −0.0386 to 0.0850) for adaptive immune therapies, and 0.0704 (95% CI, −0.0348 to 0.1756) for innate immune therapies.</p> <a class="article-section-id-anchor" id="238583292"></a> <p class="para">As previously reviewed,<sup><a href="#zoi190782r12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">12</a></sup> 4 types of combination regimens accounted for most available trial data. Combination results for these 4 regimens are shown in <a href="#zoi190782f5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 5</a>, which displays results for platinum-containing chemotherapy regimens, VEGF/R inhibitors, IDO inhibitors, and CTLA-4 inhibitors (eTable 5 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>). The largest distances between the Bliss estimated ORR and the observed ORR were seen for patients with nonsquamous cell lung cancer receiving platinum-containing chemotherapy with pembrolizumab (<i>Z</i> score, 0.28),<sup><a href="#zoi190782r14" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">14</a></sup> patients with renal cell carcinoma receiving axitinib plus pembrolizumab (<i>Z</i> score, 0.35),<sup><a href="#zoi190782r15" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">15</a></sup> and patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab (<i>Z</i> score, 0.28).<sup><a href="#zoi190782r16" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">16</a></sup> The mean (SD) <i>Z</i> score for all trials was 0.0430 (0.0243). The mean (SD) <i>Z</i> score above the Bliss calculated contribution to combination activity as a measure of clinical synergy was 0.0923 (0.0628) for platinum chemotherapy regimen combinations, 0.0547 (0.0821) for VEGF/R tyrosine kinase inhibitor combinations, 0.0893 (0.086) for IDO inhibitor combinations, and 0.0558 (0.0849) for CTLA-4 inhibitor combinations. This plot offers a systematic approach to understanding PD-1 pathway combination success based on objective mathematic principles.</p> <a class="article-section-id-anchor" id="238583294"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Discussion </div> </div> <a class="article-section-id-anchor" id="238583295"></a> <p class="para">The data compiled here demonstrated that most combination trials involving PD-1 or PD-L1 immune checkpoint inhibitors resulted in ORRs greater than expected from the PD-1 monotherapy associated with those inhibitors (<a href="#zoi190782f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>). This occurred across a broad range of indications, mechanisms, and classes of compounds. This is a key finding because it implies that PD-1 inhibitors will continue to evolve as a central part of combinations with all types of anticancer agents.</p> <a class="article-section-id-anchor" id="238583296"></a> <p class="para">We compared 2 approaches to developing PD-1 combinations: combinations using independent orthogonal agents following historic paradigms vs combinations based on immune synergy hypotheses. <a href="#zoi190782f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a> shows that, while both strategies increase antitumor activity in a large proportion of clinical trials, more chemotherapies and targeted therapies showed higher fold increases than immune strategies.</p> <a class="article-section-id-anchor" id="238583297"></a> <p class="para">Both historically<sup><a href="#zoi190782r10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup> and as agreed in consensus conferences,<sup><a href="#zoi190782r8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> the Bliss equation<sup><a href="#zoi190782r9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> is widely accepted as a valid measure of independent additivity. We applied the Bliss equation to all clinical trials in which component monotherapy ORRs were available (<a href="#zoi190782f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>). <a href="#zoi190782f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>C showed that the Bliss equation explained observed combination ORRs in nearly all the PD-1 checkpoint inhibitor clinical trials studied. Furthermore, the frequency plot of the same data (<a href="#zoi190782f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>D) showed that the average deviation from this model was 0.</p> <a class="article-section-id-anchor" id="238583298"></a> <p class="para">Clinicians will likely choose to use therapies with the highest observed ORRs regardless of the approach used to identify the combination. <a href="#zoi190782f5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 5</a> provides the observed ORRs for key combinations. However, as future combinations are designed, those developing clinical trials need to consider strategies that achieve the best antitumor effects. Consequently, we adapted the Bliss equation to identify clinical synergy (ie, the <i>Z</i> score). While the measure of clinical synergy in the compiled PD-1 combination trials was 0, clinicians will likely choose those combinations with the best ORRs. Consequently, agents with a higher <i>Z</i> score, if accompanied by a higher observed ORR, may benefit patients the most. <a href="#zoi190782f4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 4</a> provides the <i>Z</i> score for 100 combinations to show that clinical synergy can be achieved by any of the combination mechanisms reviewed here; it was not associated with immune synergy. In fact, the greatest <i>Z</i> score seen was for the most orthogonal class, ie, chemotherapies. It is important to note that the <i>Z</i> score contribution for all combinations was not the major component of response. That is, while the y-axis in <a href="#zoi190782f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a> spans a range of 0.125- to 16-fold increases in overall efficacy, the y-axis in <a href="#zoi190782f4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 4</a> spans increments from 1.3-fold decreases to 1.4-fold increases in clinical synergy.</p> <a class="article-section-id-anchor" id="238583299"></a> <p class="para">Previous reviews of the PD-1 checkpoint inhibitor landscape have shown that 4 types of compounds are tested in most PD-1 combination trials.<sup><a href="#zoi190782r17" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">17</a></sup><a href="#zoi190782f5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 5</a> provides specific data on available observed combination ORRs for the most commonly tested combinations of platinum chemotherapies, VEGF/R agents, and IDO and CTLA-4 inhibitor combinations. By plotting the observed ORR, the monotherapy ORRs, and the Bliss additive calculation, each combination can be dissected to understand how combination efficacy was achieved. Where the PD-1 monotherapy efficacy was the same as the Bliss calculation, the combination agent had no monotherapy efficacy. In this case, the combination would depend entirely on clinical synergy to achieve an increased ORR. The difference between the observed ORR and the Bliss prediction (ie, <i>Z</i> score) is the difference between the orange line and the ORR column. The most effective therapies, with the highest observed ORRs, were platinum chemotherapy and VEGF/R combinations; these therapies benefited from both independent additivity and clinical synergy—an unexpected finding for those advocating immune synergy.</p> <a class="article-section-id-anchor" id="238583300"></a> <div class="h4 cb section-type-section "> <div class="heading-text "> Limitations </div> </div> <a class="article-section-id-anchor" id="238583301"></a> <p class="para">This study has limitations. The major limitation is its dependence on phase 1 trial data. Objective response rates do not always translate to the registration end points (ie, progression-free survival and overall survival) tested in phase 3 trials. During clinical development, the ORR in an initial phase 1 or phase 2 clinical trial is likely to be the first and most commonly reported efficacy end point. Consequently, an analysis of early phase ORRs provides the broadest and earliest data set for cross-sectional studies. As noted by the FDA, the ORR is the efficacy measure most appropriate for assessing clinical activity in single-arm phase 1 trials. However, this cross-sectional survey will need further validation in future randomized phase 3 studies.</p> <a class="article-section-id-anchor" id="238583302"></a> <p class="para">To consider whether our data set largely based on phase 1 studies might be validated in the future, we listed combination regimens combining PD-1 pathway inhibitors approved by the FDA (eTable 6 in the <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-ZOI190782-1">Supplement</a>). This table shows the registration potential for PD-1 pathway inhibitor combinations using chemotherapies, targeted therapies, and CTLA-4 inhibitors. Currently, all these FDA-labeled combinations show contributions from both independent activity and clinical synergy. All approved regimens combine 2 active agents, so they benefit first from independent additivity. The observation that active drugs combine most successfully is consistent with a long-understood finding in cancer drug development; the monotherapy ORR for new agents remains the best predictor of eventual approval by regulatory agencies.<sup><a href="#zoi190782r18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup><sup>-<a href="#zoi190782r18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup></p> <a class="article-section-id-anchor" id="238583303"></a> <p class="para">In contrast, and illustrating the need for future phase 3 validations, the 2018 phase 3 trial outcome for a PD-1 checkpoint inhibitor plus IDO inhibitor<sup><a href="#zoi190782r21" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">21</a></sup> offers a caution that lack of monotherapy activity may present special challenges in moving to a phase 3 trial. As shown in <a href="#zoi190782f5" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 5</a>, the proposed combination benefit of epacadostat plus pembrolizumab was entirely dependent on a proposed clinical synergy based on immune synergy. A 2018 phase 3 trial of the pembrolizumab-epacadostat combination failed to achieve its primary end points of increased overall survival or progression-free survival.<sup><a href="#zoi190782r21" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">21</a></sup> While <i>Z</i> score for the IDO combinations was substantial (<i>Z</i> = 0.0893), this mechanism failed in a phase 3 trial.</p> <a class="article-section-id-anchor" id="238583304"></a> <div class="h3 cb section-type-section "> <div class="heading-text thm-col sb-sc"> Conclusions </div> </div> <a class="article-section-id-anchor" id="238583305"></a> <p class="para">This study showed that most clinical combinations including PD-1 or PD-L1 inhibitors demonstrated more clinical activity than the monotherapy activity of the checkpoint inhibitor alone. Most of this can be attributed to the independent contribution of the combination components. This clinical snapshot should add value to decisions about advancing immunotherapy combinations in the clinic. It highlights platinum compound–containing agents as benefitting from both independent and clinical synergy, and it identifies angiogenesis inhibition as an additional promising approach to immune therapy combinations. Given the relatively poor mechanistic understanding of PD-1 combination therapies, using small cohorts of patients in clinical studies looking for large effect sizes may be the best approach to identify optimal combinations. Overall, the success of combinations based on independent contributions of components will likely encourage the continued development of combinations of orthogonal agents with PD-1 pathway inhibitors.</p> <a class="article-section-id-anchor" id="238583306"></a> <div class="h3 cb section-type-acknowledgements has-back-to-top"> <a href="#top" class="section-jump-link back-to-top" data-tab-toggle=".tab-nav-full-text">Back to top</a> <div class="heading-text thm-col sb-sc"> Article Information </div> </div> <p class="para"><strong>Accepted for Publication:</strong> November 25, 2019.</p><p class="parapublished-online"><strong>Published:</strong> February 12, 2020. doi:10.1001/jamanetworkopen.2019.20833</p><p class="paraopen-access-note"><strong>Open Access:</strong> This is an open access article distributed under the terms of the <a href="https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors#SecOpenAccess">CC-BY-NC-ND License</a>. © 2020 Schmidt EV et al. <i>JAMA Network Open</i>.</p><p class="authorInfoSection"><strong>Corresponding Author:</strong> Emmett V. Schmidt, MD, PhD, Merck and Co, 351 N Sumneytown Pike, UG4D-34, North Wales, PA 19454 (<a href="mailto:emmett.schmidt@merck.com" target="_blank">emmett.schmidt@merck.com</a>).</p><p class="paraauthor-contributions"><strong>Author Contributions:</strong> Drs Chisamore and Uebele had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p class="para"><i>Concept and design:</i> Schmidt, Chisamore, Anderson, Uebele.</p><p class="para"><i>Acquisition, analysis, or interpretation of data:</i> Schmidt, Chisamore, Chaney, Maradeo, Baltus, Pinheiro, Uebele.</p><p class="para"><i>Drafting of the manuscript:</i> Schmidt, Chisamore, Chaney, Baltus.</p><p class="para"><i>Critical revision of the manuscript for important intellectual content:</i> All authors.</p><p class="para"><i>Statistical analysis:</i> Schmidt, Chisamore, Chaney, Anderson.</p><p class="para"><i>Administrative, technical, or material support:</i> Schmidt, Chisamore, Chaney, Maradeo, Pinheiro, Uebele.</p><p class="para"><i>Supervision:</i> Schmidt, Chisamore.</p><p class="parafinancial-disclosure"><strong>Conflict of Interest Disclosures:</strong> Dr Schmidt reported being an employee and stockholder of Merck and Co during the conduct of the study. Drs Chaney, Pinheiro, and Uebele and Ms Baltus reported being employees and potential stockholders of Merck and Co during the conduct of the study. Drs Maradeo and Anderson reported being employees of Merck and Co during the conduct of the study. No other disclosures were reported.</p><p class="parafunding-statement"><strong>Funding/Support:</strong> The authors are employees of Merck Sharp and Dohme Corp, a subsidiary of Merck and Co. The compilation of publicly presented clinical trial data was accomplished as part of their assigned jobs. No additional funding was provided for this study.</p><p class="para"><strong>Role of the Funder/Sponsor:</strong> Merck and Co had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The Office of Scientific and Technical Information Clearance at Merck and Co monitored adherence to ethical review, legal compliance, and US Food and Drug Administration compliance and reviewed and approved submission of the manuscript for those items.</p> <a class="article-section-id-anchor" id="238583307"></a> <div class="h3 cb section-type-references "> <div class="heading-text thm-col sb-sc"> References </div> </div> <div class="references"><div class="reference"><a class="reference-number" id="zoi190782r1">1.</a><div class="reference-content">Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. <i xmlns:helper="urn:XsltStringHelper"> Science</i>. 2018;359(6382):1350-1355. doi:<a href="http://dx.doi.org/10.1126/science.aar4060">10.1126/science.aar4060</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29567705" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cancer%20immunotherapy%20using%20checkpoint%20blockade.&author=A%20Ribas&author=JD%20Wolchok&publication_year=2018&journal=Science&volume=359&pages=1350-1355" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.aar4060" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.aar4060" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r2">2.</a><div class="reference-content">Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. <i xmlns:helper="urn:XsltStringHelper"> J Immunother Cancer</i>. 2017;5:16. doi:<a href="http://dx.doi.org/10.1186/s40425-017-0218-5">10.1186/s40425-017-0218-5</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/28239469" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Combination%20immunotherapy%3A%20a%20road%20map.&author=PA%20Ott&author=FS%20Hodi&author=HL%20Kaufman&author=JM%20Wigginton&author=JD%20Wolchok&publication_year=2017&journal=J%20Immunother%20Cancer&volume=5&pages=16" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1186/s40425-017-0218-5" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1186/s40425-017-0218-5" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r3">3.</a><div class="reference-content">Frei E III, Karon M, Levin RH, et al. The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia. <i xmlns:helper="urn:XsltStringHelper"> Blood</i>. 1965;26(5):642-656. doi:<a href="http://dx.doi.org/10.1182/blood.V26.5.642.642">10.1182/blood.V26.5.642.642</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/5321112" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20effectiveness%20of%20combinations%20of%20antileukemic%20agents%20in%20inducing%20and%20maintaining%20remission%20in%20children%20with%20acute%20leukemia.&author=E%20Frei&author=M%20Karon&author=RH%20Levin&publication_year=1965&journal=Blood&volume=26&pages=642-656" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1182/blood.V26.5.642.642" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1182/blood.V26.5.642.642" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r4">4.</a><div class="reference-content">Law LW. Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. <i xmlns:helper="urn:XsltStringHelper"> Cancer Res</i>. 1952;12(12):871-878.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/13009674" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20combinations%20of%20antileukemic%20agents%20on%20an%20acute%20lymphocytic%20leukemia%20of%20mice.&author=LW%20Law&publication_year=1952&journal=Cancer%20Res&volume=12&pages=871-878" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r5">5.</a><div class="reference-content">DeVita VT Jr. The James Ewing lecture: the relationship between tumor mass and resistance to chemotherapy–implications for surgical adjuvant treatment of cancer. <i xmlns:helper="urn:XsltStringHelper"> Cancer</i>. 1983;51(7):1209-1220. doi:<a href="http://dx.doi.org/10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO;2-J">10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO;2-J</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/6825044" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20James%20Ewing%20lecture%3A%20the%20relationship%20between%20tumor%20mass%20and%20resistance%20to%20chemotherapy%E2%80%93implications%20for%20surgical%20adjuvant%20treatment%20of%20cancer.&author=VT%20DeVita&publication_year=1983&journal=Cancer&volume=51&pages=1209-1220" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1002/(ISSN)1097-0142" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1002/(ISSN)1097-0142" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r6">6.</a><div class="reference-content">Center for Drug Evaluation and Research. Clinical trial endpoints for the approval of cancer drugs and biologics. <a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics</a>. Accessed December 27, 2019.</div></div><div class="reference"><a class="reference-number" id="zoi190782r7">7.</a><div class="reference-content">Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. <i xmlns:helper="urn:XsltStringHelper"> Pharmacol Res Perspect</i>. 2015;3(3):e00149. doi:<a href="http://dx.doi.org/10.1002/prp2.149">10.1002/prp2.149</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/26171228" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Analysis%20of%20drug%20combinations%3A%20current%20methodological%20landscape.&author=J%20Foucquier&author=M%20Guedj&publication_year=2015&journal=Pharmacol%20Res%20Perspect&volume=3&pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r8">8.</a><div class="reference-content">Greco W, Unkelbach HD, Pöch G, Sühnel J, Kundi M, Bödeker W. Consensus on concepts and terminology for combined-action assessment: The Saariselkä agreement. <i xmlns:helper="urn:XsltStringHelper"> Arch Complex Environ Stud</i>. 1992;4:65-69. <a href="http://www.xn--tyelmosaaminen-8hbb51a.fi/aces/Greco%20et%20al%20Aces%204(3)1992.pdf">http://www.xn--tyelmosaaminen-8hbb51a.fi/aces/Greco%20et%20al%20Aces%204(3)1992.pdf</a>. Accessed December 27, 2019.<a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Consensus%20on%20concepts%20and%20terminology%20for%20combined-action%20assessment%3A%20The%20Saariselk%C3%A4%20agreement.&author=W%20Greco&author=HD%20Unkelbach&author=G%20Pöch&author=J%20Sühnel&author=M%20Kundi&author=W%20Bödeker&publication_year=1992&journal=Arch%20Complex%20Environ%20Stud&volume=4&pages=65-69" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r9">9.</a><div class="reference-content">Bliss CI. The toxicity of poisons applied jointly. <i xmlns:helper="urn:XsltStringHelper"> Ann Appl Biol</i>. 1939;26(3):585-615. doi:<a href="http://dx.doi.org/10.1111/j.1744-7348.1939.tb06990.x">10.1111/j.1744-7348.1939.tb06990.x</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20toxicity%20of%20poisons%20applied%20jointly.&author=CI%20Bliss&publication_year=1939&journal=Ann%20Appl%20Biol&volume=26&pages=585-615" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1111/j.1744-7348.1939.tb06990.x" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1111/j.1744-7348.1939.tb06990.x" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r10">10.</a><div class="reference-content">Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. <i xmlns:helper="urn:XsltStringHelper"> Pharmacol Rev</i>. 1995;47(2):331-385.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/7568331" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20search%20for%20synergy%3A%20a%20critical%20review%20from%20a%20response%20surface%20perspective.&author=WR%20Greco&author=G%20Bravo&author=JC%20Parsons&publication_year=1995&journal=Pharmacol%20Rev&volume=47&pages=331-385" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="zoi190782r11">11.</a><div class="reference-content">Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. <i xmlns:helper="urn:XsltStringHelper"> Immunity</i>. 2013;39(1):1-10. doi:<a href="http://dx.doi.org/10.1016/j.immuni.2013.07.012">10.1016/j.immuni.2013.07.012</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/23890059" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Oncology%20meets%20immunology%3A%20the%20cancer-immunity%20cycle.&author=DS%20Chen&author=I%20Mellman&publication_year=2013&journal=Immunity&volume=39&pages=1-10" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.immuni.2013.07.012" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.immuni.2013.07.012" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r12">12.</a><div class="reference-content">Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. <i xmlns:helper="urn:XsltStringHelper"> Ann Oncol</i>. 2018;29(1):84-91. doi:<a href="http://dx.doi.org/10.1093/annonc/mdx755">10.1093/annonc/mdx755</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29228097" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Comprehensive%20analysis%20of%20the%20clinical%20immuno-oncology%20landscape.&author=J%20Tang&author=A%20Shalabi&author=VM%20Hubbard-Lucey&publication_year=2018&journal=Ann%20Oncol&volume=29&pages=84-91" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/annonc/mdx755" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/annonc/mdx755" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r13">13.</a><div class="reference-content">Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. <i xmlns:helper="urn:XsltStringHelper"> Cell</i>. 2017;171(7):1678-1691.e13.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/29245013" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Combination%20cancer%20therapy%20can%20confer%20benefit%20via%20patient-to-patient%20variability%20without%20drug%20additivity%20or%20synergy.&author=AC%20Palmer&author=PK%20Sorger&publication_year=2017&journal=Cell&volume=171&pages=1678-1691.e13" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.cell.2017.11.009" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.cell.2017.11.009" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r14">14.</a><div class="reference-content">Gadgeel SM, Stevenson J, Langer CJ, et al. Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2016;34(15)(Suppl):9016. doi:<a href="http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.9016">10.1200/JCO.2016.34.15_suppl.9016</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab%20%28pembro%29%20plus%20chemotherapy%20as%20front-line%20therapy%20for%20advanced%20NSCLC%3A%20KEYNOTE-021%20cohorts%20A-C.&author=SM%20Gadgeel&author=J%20Stevenson&author=CJ%20Langer&publication_year=2016&journal=J%20Clin%20Oncol&volume=34&pages=9016" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2016.34.15_suppl.9016" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2016.34.15_suppl.9016" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r15">15.</a><div class="reference-content">Atkins MB, Plimack ER, Puzanov I, et al. Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2018;36(6)(Suppl):579. doi:<a href="http://dx.doi.org/10.1200/JCO.2018.36.6_suppl.579">10.1200/JCO.2018.36.6_suppl.579</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20efficacy%20of%20axitinib%20%28axi%29%20in%20combination%20with%20pembrolizumab%20%28pembro%29%20in%20patients%20%28pts%29%20with%20advanced%20renal%20cell%20cancer%20%28aRCC%29.&author=MB%20Atkins&author=ER%20Plimack&author=I%20Puzanov&publication_year=2018&journal=J%20Clin%20Oncol&volume=36&pages=579" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2018.36.6_suppl.579" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2018.36.6_suppl.579" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r16">16.</a><div class="reference-content">Lee C-H, Makker V, Rasco DW, et al. Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results. <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2018;36(15)(Suppl):4560. doi:<a href="http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.4560">10.1200/JCO.2018.36.15_suppl.4560</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Lenvatinib%20%2B%20pembrolizumab%20in%20patients%20with%20renal%20cell%20carcinoma%3A%20updated%20results.&author=C-H%20Lee&author=V%20Makker&author=DW%20Rasco&publication_year=2018&journal=J%20Clin%20Oncol&volume=36&pages=4560" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.4560" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2018.36.15_suppl.4560" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r17">17.</a><div class="reference-content">Tang J, Pearce L, O’Donnell-Tormey J, Hubbard-Lucey VM. Trends in the global immuno-oncology landscape. <i xmlns:helper="urn:XsltStringHelper"> Nat Rev Drug Discov</i>. 2018;17(12):922.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/30361553" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Trends%20in%20the%20global%20immuno-oncology%20landscape.&author=J%20Tang&author=L%20Pearce&author=J%20O’Donnell-Tormey&author=VM%20Hubbard-Lucey&publication_year=2018&journal=Nat%20Rev%20Drug%20Discov&volume=17&pages=922" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/nrd.2018.202" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/nrd.2018.202" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r18">18.</a><div class="reference-content">Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, Schwartz LH. Response rate as a regulatory end point in single-arm studies of advanced solid tumors. <i xmlns:helper="urn:XsltStringHelper"> JAMA Oncol</i>. 2016;2(6):772-779. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2015.6315">10.1001/jamaoncol.2015.6315</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/26914340" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Response%20rate%20as%20a%20regulatory%20end%20point%20in%20single-arm%20studies%20of%20advanced%20solid%20tumors.&author=GR%20Oxnard&author=KH%20Wilcox&author=M%20Gonen&author=M%20Polotsky&author=BR%20Hirsch&author=LH%20Schwartz&publication_year=2016&journal=JAMA%20Oncol&volume=2&pages=772-779" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jamaoncol.2015.6315" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jamaoncol.2015.6315" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r19">19.</a><div class="reference-content">Goffin J, Baral S, Tu D, Nomikos D, Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. <i xmlns:helper="urn:XsltStringHelper"> Clin Cancer Res</i>. 2005;11(16):5928-5934. doi:<a href="http://dx.doi.org/10.1158/1078-0432.CCR-05-0130">10.1158/1078-0432.CCR-05-0130</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/16115935" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Objective%20responses%20in%20patients%20with%20malignant%20melanoma%20or%20renal%20cell%20cancer%20in%20early%20clinical%20studies%20do%20not%20predict%20regulatory%20approval.&author=J%20Goffin&author=S%20Baral&author=D%20Tu&author=D%20Nomikos&author=L%20Seymour&publication_year=2005&journal=Clin%20Cancer%20Res&volume=11&pages=5928-5934" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1158/1078-0432.CCR-05-0130" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1158/1078-0432.CCR-05-0130" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r20">20.</a><div class="reference-content">Sekine I, Yamamoto N, Kunitoh H, et al. Relationship between objective responses in phase I trials and potential efficacy of non-specific cytotoxic investigational new drugs. <i xmlns:helper="urn:XsltStringHelper"> Ann Oncol</i>. 2002;13(8):1300-1306. doi:<a href="http://dx.doi.org/10.1093/annonc/mdf202">10.1093/annonc/mdf202</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/12181255" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Relationship%20between%20objective%20responses%20in%20phase%20I%20trials%20and%20potential%20efficacy%20of%20non-specific%20cytotoxic%20investigational%20new%20drugs.&author=I%20Sekine&author=N%20Yamamoto&author=H%20Kunitoh&publication_year=2002&journal=Ann%20Oncol&volume=13&pages=1300-1306" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/annonc/mdf202" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/annonc/mdf202" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="zoi190782r21">21.</a><div class="reference-content">Long GV, Dummer R, Hamid O, et al. Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study. <i xmlns:helper="urn:XsltStringHelper"> J Clin Oncol</i>. 2018;36(15)(Suppl):108. doi:<a href="http://dx.doi.org/10.1200/JCO.2018.36.15_suppl.108">10.1200/JCO.2018.36.15_suppl.108</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Epacadostat%20%28E%29%20plus%20pembrolizumab%20%28P%29%20versus%20pembrolizumab%20alone%20in%20patients%20%28pts%29%20with%20unresectable%20or%20metastatic%20melanoma%3A%20results%20of%20the%20phase%203%20ECHO-301%2FKEYNOTE-252%20study.&author=GV%20Long&author=R%20Dummer&author=O%20Hamid&publication_year=2018&journal=J%20Clin%20Oncol&volume=36&pages=108" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1200/JCO.2018.36.15_suppl.108" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1200/JCO.2018.36.15_suppl.108" xmlns:helper="urn:XsltStringHelper"> </span></div></div></div> </div> </div> <div class="movable-ad bta"> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_textbreak_bta_dual"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_textbreak_bta_dual" data-params="{"parameters":{"siteName":"jamanetworkopen","siteId":214,"journalId":187,"adDisplay":8,"adSection":"textbreak","adPosition":"bta","fromGoogle":false},"dynamicParameters":{}}"></div> </div> </div> </div> </div> <div class="hidden-jobs-ad hide"> <div class="widget-WidgetLoader widget-instance-AMA_JobsAd"> <div class="SCM-SharedWidgets-AsyncJobsAdLoader" data-url="/AMA/JobsAd/AMA_JobsAd" data-params="{"parameters":{"SiteId":214},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> <script> var App = App || {}; App.ArticleSplitScreen = App.ArticleSplitScreen || {}; App.ArticleSplitScreen.siteName = 'jamanetworkopen'; App.ArticleSplitScreen.siteId = 214; App.ArticleSplitScreen.journalId = 187; App.ArticleSplitScreen.adDisplay = 'ArticleContentsSkyBox'; App.ArticleSplitScreen.adSection = "scholarly"; App.ArticleSplitScreen.adPosition = "contab"; App.ArticleSplitScreen.controlId = "AMA_AdTag_Contents_Skybox"; App.ArticleSplitScreen.fromGoogle = "False"; App.ArticleSplitScreen.slotLocationOverride = "50"; </script> </div> </div> </section> <section id="secFooterControl" class="master-footer"> <script> var App = App || {}; function scmByClass(className) { return document.getElementsByClassName(className); } function scmById(id) { return document.getElementById(id); } function scmquery(selector) { return document.querySelector(selector); } function queryAll(selector) { return document.querySelectorAll(selector); } function isTrueString(string) { if (typeof string === 'string') { return string.toLowerCase() === 'true'; } return undefined; } function updateViewportDimensions() { var w = window, d = document, e = d.documentElement, g = d.getElementsByTagName('body')[0], x = w.innerWidth || e.clientWidth || g.clientWidth, y = w.innerHeight || e.clientHeight || g.clientHeight; return { width: x, height: y }; } var viewport = updateViewportDimensions(); var debounce = function (func, wait, immediate) { var timeout; return function () { var context = this, args = arguments; var later = function () { timeout = null; if (!immediate) func.apply(context, args); }; var callNow = immediate && !timeout; clearTimeout(timeout); timeout = setTimeout(later, wait); if (callNow) func.apply(context, args); }; }; (function (App) { App.mobileUpperBreakpoint = 767; App.mobileAltBreakpoint = 640; App.mobileMinBreakpoint = 547; App.tabletUpperBreakpoint = 1023; function setVariables() { viewport = updateViewportDimensions(); App.isMobile = (viewport.width <= App.mobileUpperBreakpoint); App.isMobileAlt = (viewport.width <= App.mobileAltBreakpoint); App.isTablet = (viewport.width > App.mobileUpperBreakpoint && viewport.width <= App.tabletUpperBreakpoint); App.isTabletDown = (viewport.width <= App.tabletUpperBreakpoint); App.isDesktop = (viewport.width > App.tabletUpperBreakpoint); App.activeViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large'; } setVariables(); App.cachedViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large'; App.isAnyArticle = !!(scmByClass('widget-ArticleFullView').length || scmByClass('pg_abstract').length || scmByClass('widget-MagazineView').length || scmByClass('widget-ChannelsMagazineView').length); App.isSplitScreen = !!scmByClass('widget-ArticleFullView').length; App.isArticleRedesign = !!scmByClass('widget-ArticleWrapper').length; App.isAbstract = !!scmByClass('pg_abstract').length; App.isMag = !!(scmByClass('widget-MagazineView').length); App.isChannel = !!(scmByClass('channel-site').length); App.isChannelMag = !!(scmByClass('widget-ChannelsMagazineView').length); App.isFreeArticle = !!(scmquery('.widget-ArticleTopInfo .free-access') || scmquery('.widget-ArticleTopInfo .open-access') || scmquery('.widget-ArticleTopInfo .icon-free') || scmquery('.widget-ChannelsMagazineView .free-access')); App.isTollFreeAccess = false; App.isIssue = !!scmByClass('pg_issue').length || !!scmByClass('pg_newonline').length || !!scmByClass('pg_currentissue').length || !!scmByClass('pg_pastissues').length; App.isNewOnline = !!scmByClass('pg_newonline').length; App.isCurrentIssue = !!scmByClass('pg_currentissue').length; App.isPastIssues = !!scmByClass('pg_pastissues').length; App.isJournal = !!scmByClass('pg_journal').length; App.isNetworkHome = !!scmByClass('pg_index').length; App.isSearch = !!scmByClass('pg_searchresults').length; App.isAdvancedSearch = !!scmByClass('pg_advancedsearch').length; App.isPlayer= !!scmByClass('pg_multimediaplayer').length; App.isSelfServe = !!scmByClass('pg_sspage').length; App.isCmsPage = !!scmByClass('pg_cmspage').length; App.isMyAccount = !!scmByClass('pg_myaccount').length; App.supportsFlexbox = !!scmByClass('flexbox').length; App.isCollection = !!scmByClass('pg_collection').length; App.isPaidUser = isTrueString(scmById('hfAppIsPaidUser').getAttribute('value')); App.isMember = isTrueString(scmById('hfAppIsMember').getAttribute('value')); App.isIndividual = isTrueString(scmById('hfAppIsIndividual').getAttribute('value')); App.hasAccess = isTrueString(scmById('hfAppHasAccess').getAttribute('value')); App.isReferredFromGoogle = isTrueString(scmById('hfAppIsReferredFromGoogle').getAttribute('value')); var subscribedTo = scmById('hfAppSubscribedTo').getAttribute('value'); App.userSubscribedTo = subscribedTo ? subscribedTo.split(',') : undefined; App.isLucy = isTrueString(scmById('hfAppIsLucy').getAttribute('value')); App.currentJournalCount = 27; App.isChannelPage = !!(scmByClass('channels-page')); App.updateAppVariables = debounce(function () { setVariables(); }, 50, false); })(App); </script> <div class="footer-ad-wrapper"> <div id="BodyContent_Footer_divAds" class="footer-ad desktop-only"> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_AnchorboardAd_btf"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_AnchorboardAd_btf" data-params="{"parameters":{"siteName":"jamanetworkopen","siteId":214,"journalId":187,"adDisplay":11,"adSection":"scholarly","adPosition":"btf","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> </div> <div class="ad-riser-wrap desktop-only"> <div class="ad-riser--dismiss t-c">X</div> <div class="widget-WidgetLoader widget-instance-AMA_AdTag_Riser"> <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_Riser" data-params="{"parameters":{"siteName":"jamanetworkopen","siteId":214,"journalId":187,"adDisplay":12,"adSection":"scholarly","adPosition":"Riser","fromGoogle":false},"dynamicParameters":{"localParams":"[REPLACE_WITH_LOCAL]"}}"></div> </div> </div> <div class="footer-wrap"> <footer class="footer" id="footer"> <div id="footer-microsite" class="footer-microsite"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Left" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> @media (min-width: 1024px) {.split-screen .footer-microsite-contents {border-bottom:0 !important;}} .footer-microsite-contents {margin-bottom:1em;width:100%;} .footer-network-other .link-apps:before {width: 23px;} .footer-network-other .link-institutions-librarians:before {width: 23px;} .jn-ss-footer-border-top {border-top:1px solid #555;padding-top:15px;} .jn-ss-footer-border-bottom {border-bottom:1px solid #555;padding-bottom:10px;} /* .article-full-text .languageTranslateLink {display: none;}*/ </style> <div class="footer-heading-wrap"> <h3 id="BodyContent_Footer_h3SiteName" class="footer-heading is-b footer-microsite-heading" data-mobile-tog-target=".footer-microsite-links-wrap">JAMA Network Open</h3> </div> <div class="footer-microsite-links-wrap"> <div class="footer-microsite-contents jn-ss-footer-border-bottom"> <h4 id="BodyContent_Footer_ContentHeader" class="footer-subheading">Content</h4> <a href="/journals/jamanetworkopen">Home</a> <a href="/journals/jamanetworkopen/newonline">New Online</a> <a href="/journals/jamanetworkopen/currentissue">Current Issue</a> </div> <div class="footer-microsite-contents jn-ss-footer-border-bottom"> <h4 class="footer-subheading">Podcast</h4> <a href="/journals/jamanetworkopen/pages/jama-network-open-editors-summary">JAMA Network Open Editors' Summary</a> </div> <div class="footer-microsite-services cf"> <h4 id="BodyContent_Footer_ServiceHeader" class="footer-subheading">Journal Information</h4> <a href="/journals/jamanetworkopen/pages/for-authors">For Authors</a> <a href="/journals/jamanetworkopen/editors-and-publishers">Editors & Publishers</a> <a href="/pages/rss">RSS</a> <a href="/journals/jamanetworkopen/pages/contact-us">Contact Us</a> </div> <div class="footer-network-other jn-ss-footer-border-bottom"> <a href="https://edhub.ama-assn.org/jn-learning" class="link-network-other is-b link-learning">JN Learning / CME</a> <a href="https://store.jamanetwork.com" class="link-network-other is-b link-store" target="_blank">Store</a> <a href="/pages/apps" class="link-network-other is-b link-mobile" target="_blank">Apps</a> <a href="https://careers.jamanetwork.com/" class="link-network-other is-b link-jobs" target="_blank">Jobs</a> <a href="/pages/resources-for-librarians" class="link-network-other is-b link-institutions-librarians" target="_blank">Institutions</a> <a href="/pages/reprints-and-permissions" class="link-network-other is-b link-reprints-permissions">Reprints & Permissions</a> </div> </div> </div> <div id="footer-network" class="footer-network"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Middle" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .footer-network-sites {width: 62.85542%;} .footer-network-info {width: 35.93976%} .jn-ss-subheading-mt {margin-top: 1.5em;} .jn-registered:after {content: "\00AE";font-size: 50%;vertical-align: top;} .jn-trademark:after {content: "\2122";font-size: 50%;vertical-align: top;} .nav-logo-cme-signin-container .nav-logo .site-logo img { min-width:50px;} </style> <div class="footer-heading-wrap"> <h3 class="footer-heading is-b jn-registered" data-mobile-tog-target=".footer-network-links-wrap"><strong>JAMA</strong> Network</h3> </div> <div class="footer-network-links-wrap"> <div class="footer-network-sites"> <div class="internal"> <h4 id="BodyContent_Footer_JournalHeader" class="footer-subheading">Publications</h4> <a href="/journals/jama">JAMA</a> <a href="/journals/jamanetworkopen" target="_blank">JAMA Network Open</a> <a href="/journals/jamacardiology">JAMA Cardiology</a> <a href="/journals/jamadermatology">JAMA Dermatology</a> <a href="/journals/jama-health-forum">JAMA Health Forum</a> <a href="/journals/jamainternalmedicine">JAMA Internal Medicine</a> <a href="/journals/jamaneurology">JAMA Neurology</a> <a href="/journals/jamaoncology">JAMA Oncology</a> <a href="/journals/jamaophthalmology">JAMA Ophthalmology</a> <a href="/journals/jamaotolaryngology">JAMA Otolaryngology–Head & Neck Surgery</a> <a href="/journals/jamapediatrics">JAMA Pediatrics</a> <a href="/journals/jamapsychiatry">JAMA Psychiatry</a> <a href="/journals/jamasurgery">JAMA Surgery</a> <a href="/journals/archneurpsyc">Archives of Neurology & Psychiatry (1919-1959)</a> </div> <div class="external"> <h4 class="footer-subheading">Sites</h4> <div id="BodyContent_Footer_ssFooterSiteMenu"> <div class="selfServe"> <a target="_blank" href="https://sites.jamanetwork.com/art-and-images-in-psychiatry/">Art and Images in Psychiatry</a> <a target="_blank" href="/journals/jama/pages/2023-most-viewed-jama">Best of the JAMA Network</a> <a target="_blank" href="/channels/caring-for-the-critically-ill-patient">Caring for the Critically Ill Patient</a> <a target="_blank" href="/journals/jama/pages/crosswords">Clinical Crosswords from JAMA</a> <a target="_blank" href="/journals/jama/pages/coronavirus-alert">Coronavirus Resource Center</a> <a target="_blank" href="https://ebm.jamanetwork.com/index.html">Evidence-Based Medicine: An Oral History</a> <a target="_blank" href="/pages/fishbein-fellowship">Fishbein Fellowship</a> <a target="_blank" href="/channels/genomics/">Genomics and Precision Health</a> <a target="_blank" href="/pages/health-and-the-2024-us-election">Health and the 2024 US Election</a> <a target="_blank" href="/channels/hypertension">Hypertension</a> <a target="_blank" href="/channels/health-forum/archive">JAMA Forum Archive</a> <a target="_blank" href="https://sites.jamanetwork.com/audio">JAMA Network Audio</a> <a target="_blank" href="/pages/video">JAMA Network Video</a> <a target="_blank" href="/pages/conferences">JAMA Network Conferences </a> <a target="_blank" href="/channels/ai">JAMA+ AI</a> <a target="_blank" href="/pages/jama-summit">JAMA Summit </a> <a target="_blank" href="/journals/jamasurgery/pages/statistics-and-methods">JAMA Surgery Guide to Statistics and Methods</a> <a target="_blank" href="/channels/medical-news">Medical News</a> <a target="_blank" href="/channels/monkeypox">Mpox (Monkeypox)</a> <a target="_blank" href="https://sites.jamanetwork.com/research-ethics/">Research Ethics</a> <a target="_blank" href="/pages/collections">Topics and Collections</a> <a target="_blank" href="/pages/visual-abstracts">Visual Abstracts</a> <a target="_blank" href="/channels/war">War and Health</a> <a target="_blank" href="/channels/womens-health">Women's Health</a> <h4 class="footer-subheading jn-ss-subheading-mt">Featured Articles</h4> <a href="/journals/jama/fullarticle/2781397">CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic</a> <a href="/journals/jama/fullarticle/2808296">Creation and Adoption of Large Language Models in Medicine</a> <a href="/journals/jamaoncology/fullarticle/2787350">Global Burden of Cancer, 2010-2019</a> <a href="/journals/jama/fullarticle/2797443">Global Burden of Long COVID</a> <a href="/journals/jamadermatology/fullarticle/2790344">Global Burden of Melanoma</a> <a href="/journals/jamadermatology/fullarticle/2787350">Global Burden of Skin Diseases, 1990-2017</a> <a href="/journals/jamaneurology/fullarticle/2793874">Global Disparities in Parkinson Disease</a> <a href="/journals/jama/fullarticle/2799547">Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension</a> <a href="/journals/jamapsychiatry/fullarticle/2799486">Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning</a> <a href="/journals/jamapsychiatry/fullarticle/2793903">Neuropsychiatry Sequelae of COVID-19</a> <a href="/journals/jamaneurology/fullarticle/2810313">A New Framework for Dementia Nomenclature</a> <a href="/journals/jama/fullarticle/2800656">Organization and Performance of US Health Systems</a> <a href="/journals/jama-health-forum/fullarticle/2791195">Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy</a> <a href="/journals/jama-health-forum/fullarticle/2791195">Promoting EDI in Genetics Research</a> <a href="/journals/jamacardiology/fullarticle/2781972">PTSD and Cardiovascular Disease</a> <a href="/journals/jama/fullarticle/2810754">Red Blood Cell Transfusion: 2023 AABB International Guidelines</a> <a href="/journals/jamapediatrics/fullarticle/2797600">Reimagining Children’s Rights in the US</a> <a href="/journals/jama/fullarticle/2794049">Spirituality in Serious Illness and Health</a> <a href="/journals/jama/fullarticle/2796374">The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity</a> <h4 class="footer-subheading jn-ss-subheading-mt">USPSTF Recommendation Statements</h4> <a href="/journals/jama/fullarticle/2779985">Screening for Colorectal Cancer</a> <a href="/journals/jama/fullarticle/2779190">Screening for Hypertension</a> <a href="/journals/jama/fullarticle/2777244">Screening for Lung Cancer</a> <a href="/journals/jama/fullarticle/2796244">Screening for Prediabetes and Type 2 Diabetes In Children</a> <a href="/journals/jama/fullarticle/2783414">Screening for Prediabetes and Type 2 Diabetes In Adults</a> <a href="/journals/jama/fullarticle/2795521">Statins for Primary Prevention of Cardiovascular Disease</a> <a href="/journals/jama/fullarticle/2793446">Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer</a> <h4 class="footer-subheading jn-ss-subheading-mt">Blogs</h4> <a target="_blank" href="https://amastyleinsider.com/">AMA Style Insider</a> </div> </div> </div> </div> <div id="footer-network-info" class="footer-network-info"> <div class="information-for-links"> <h4 id="BodyContent_Footer_InfoHeader" class="footer-subheading">Information</h4> <a href="/pages/for-authors">For Authors</a> <a href="/pages/resources-for-librarians">For Institutions & Librarians</a> <a href="/pages/advertisers">For Advertisers</a> <a href="/pages/subscription-agents">For Subscription Agents</a> <a href="https://careers.jamanetwork.com/" target="_blank">For Employers & Job Seekers</a> <a href="https://media.jamanetwork.com" rel="nofollow" target="_blank">For the Media</a> <a href="/pages/equity-diversity-inclusion">Equity, Diversity, Inclusion</a> <a href="/pages/commenting-policy">Online Commenting Policy</a> <a href="/pages/access-at-jama-network">Public Access and Open Access Policy</a> <a href="/pages/offensive-content-statement">Statement on Potentially Offensive Content</a> </div> <div class="services-links"> <h4 id="BodyContent_Footer_JAMANetworkProductsHeader" class="footer-subheading">JAMA Network Products</h4> <a href="http://www.amamanualofstyle.com/" class="footer-service-link" target="_blank">AMA Manual of Style</a> <a href="https://jamaevidence.mhmedical.com/" class="footer-service-link" target="_blank"><span class="jn-registered">JAMAevidence</span></a> <a href="http://www.peerreviewcongress.org/" class="footer-service-link" target="_blank">Peer Review Congress</a> </div> <div class="learning-links"> <h4 id="BodyContent_Footer_LearningHeader" class="footer-subheading">JN Learning</h4> <a href="https://edhub.ama-assn.org/jn-learning">Home</a> <a href="https://edhub.ama-assn.org/jn-learning/state-cme">State CME</a> <a href="https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses">Clinical Challenge CME</a> <a href="https://edhub.ama-assn.org/jn-learning/course/288 ">Atrial Fibrillation Course</a> <a href="https://edhub.ama-assn.org/jn-learning/course/294 ">Women's Health Course</a> <a target="_blank" href="https://edhub.ama-assn.org/pages/auto-credit-reporting">CME / MOC Reporting Preferences</a> <a href="https://edhub.ama-assn.org/jn-learning/pages/about-cme">About CME & MOC</a> </div> </div> </div> </div> <div id="footer-resources-wrap" class="footer-resources-wrap"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Right" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .footer-resources-wrap .footer-subheading {color: grey;display:block !important;font-size: 1.17647em;font-weight: 400;text-transform: uppercase;} </style> <div class="footer-heading-wrap"> <h3 class="footer-heading is-b footer-resources-heading" data-mobile-tog-target=".footer-resources">Help</h3> </div> <div class="footer-resources"> <a href="https://store.jamanetwork.com" class="footer-service-link" target="_blank">Subscriptions & Renewals</a> <a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts" class="footer-service-link" rel="nofollow">Manage Emails</a> <a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile" class="footer-service-link" rel="nofollow">Update My Address</a> <a href="https://support.jamanetwork.com/hc/en-us" class="footer-service-link">Support Center</a> <a href="/myaccount " class="footer-service-link">My Account</a> <h4 class="footer-subheading jn-ss-subheading-mt">JAMA Career Center</h4> <a href="https://careers.jamanetwork.com/" class="footer-service-link" target="_blank">Physician Job Listings</a> </div> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Socials" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .widget-instance-AMA_JNOpen_Journal_Home_Socials .iconsocial {display: inline-block !important;width: 34px;height: 34px;min-width: unset !important;margin: 0 2px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;} .widget-instance-AMA_JNOpen_Journal_Home_Socials .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 7px 7px;background-repeat: no-repeat;background-size: 18px;} .widget-instance-AMA_JNOpen_Journal_Home_Socials .iconsocial.instagram:hover, .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:focus {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png);border-color: #C13584;} .footer-resources-wrap .iconsocial {display: inline-block !important;width: 32px;height: 32px;min-width: unset !important;margin: 0 2px 0 3px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;} .footer-resources-wrap .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 6px 6px;background-repeat: no-repeat;background-size: 18px;} .footer-resources-wrap .iconsocial.instagram:hover, .footer-resources-wrap .iconsocial.instagram:focus {background-color: #C13584;border-color: #191919;} #load-instagram-image { background: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png) no-repeat -9999px -9999px; } </style> <div id="BodyContent_Footer_divSocial" class="social-links footer-social-links"> <a target="_blank" rel="nofollow" data-emailid="94df5f5e-34c6-4141-a1fb-b9a250113184" href="https://www.facebook.com/jamanetworkopen/" class="social-link is-b facebook"></a> <a target="_blank" rel="nofollow" data-emailid="94df5f5e-34c6-4141-a1fb-b9a250113184" href="https://twitter.com/jamanetworkopen" class="social-link is-b twitter"></a> <a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.instagram.com/jamanetwork/?hl=en" class="iconsocial instagram"></a> <a target="_blank" rel="nofollow" data-emailid="94df5f5e-34c6-4141-a1fb-b9a250113184" href="https://www.linkedin.com/showcase/jamanetworkopen/" class="social-link is-b linked-in"></a> <a target="_blank" rel="nofollow" data-emailid="94df5f5e-34c6-4141-a1fb-b9a250113184" href="https://ja.ma/jnoyt" class="social-link is-b you-tube"></a> <a target="_blank" rel="nofollow" data-emailid="94df5f5e-34c6-4141-a1fb-b9a250113184" href="https://www.pinterest.com/jamanetwork/" class="social-link is-b pinterest"></a> <a target="_blank" rel="nofollow" data-emailid="94df5f5e-34c6-4141-a1fb-b9a250113184" href="/rss/site_214/187.xml" class="social-link is-b rss"></a> <a target="_blank" rel="nofollow" data-emailid="94df5f5e-34c6-4141-a1fb-b9a250113184" href="https://jamanetwork.com/journals/jamanetworkopen/pages/jama-network-open-editors-summary" class="social-link is-b podcast"></a> <div id="load-instagram-image"></div> </div> <div id="BodyContent_Footer_divEmailUpdate" class="footer-email-updates"> <div class="widget-EmailListSignUp widget-instance-AMAv2_EmailListSignUp_Footer"> <div class="email-signup"> <div class="email-signup--text sb-pc">Get the latest from JAMA Network Open</div> <div class="email-signup--input-wrap is-b"> <input type="text" name="email" class="email-signup--input" placeholder="Email address" title="Email address" /> <a rel="nofollow" href="javascript:;" class="email-signup--submit sb-sc btn">Sign Up</a> </div> <div class="email-signup--link"> <a class="email-signup--privacy" href="/pages/privacy-policy">Privacy Policy</a> | <a class="email-signup--terms" href="/pages/terms-of-use">Terms of Use</a></div> <div class="email-signup--user-message"></div> </div> </div> </div> </div> <div class="footer-bar" itemscope itemtype="https://schema.org/Organization"> <input type="hidden" class="SelfServeContentId" value="v2_Footer_Bottom_Bar" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <style type="text/css"> .network-bar .auth--inst {color:#B8B8B8;} .multimedia-caption-container div.video-caption {color: #262626;font-size: 15px;font-weight: 700;line-height: 1.5;} .nav-journals a.theme-jama-health-forum:before {background: #133763;} .jn-bottom-bar {color: #fff; float: left;font-size: 10px;padding: 13px 20px;width: 33.33%;} .jn-bottom-bar p {line-height: 2;} @media (max-width: 900px) {.jn-bottom-bar {float: none;width: 100%;}} .jn-footer-copyright {font-size:12px;line-height:1.5;margin-bottom:10px;} .jn-footer-pipe {margin:0 10px;} .footer-bar-jn-logo img {width: 230px;} @media (max-width: 900px) {.footer-bar-jn-logo img {width: 200px;}} [data-thm=umb] .jobs-ad--text h6 {color: #d71635 !important;} [data-thm=jama] .jobs-ad--text h6 {color: #d71635 !important;} [data-thm=jaman] .jobs-ad--text h6 {color: #ed0973 !important;} [data-thm=cardi] .jobs-ad--text h6 {color: #be1e32 !important;} [data-thm=derm] .jobs-ad--text h6 {color: #006f3b !important;} [data-thm=faci] .jobs-ad--text h6 {color: #ed1c24 !important;} [data-thm=jama-] .jobs-ad--text h6 {color: #fb5252 !important;} [data-thm=intem] .jobs-ad--text h6 {color: #006e96 !important;} [data-thm=neur] .jobs-ad--text h6 {color: #981b1e !important;} [data-thm=oncol] .jobs-ad--text h6 {color: #3b923f !important;} [data-thm=ophth] .jobs-ad--text h6 {color: #66bc29 !important;} [data-thm=otol] .jobs-ad--text h6 {color: #34b6e4 !important;} [data-thm=peds] .jobs-ad--text h6 {color: #0084c0 !important;} [data-thm=psych] .jobs-ad--text h6 {color: #005276 !important;} [data-thm=surg] .jobs-ad--text h6 {color: #f47920 !important;} .blockquote .para {margin: 0 0 1em 1em;} .jn-footer-copyright {display: block;} .inline-block {display: inline-block;} </style> <a class="footer-bar-jn-logo d-b no-mw mb1" href="/" title="JAMA Network Home"><img class="mw-100" src="https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=82308" alt="Jama Network Logo"></a> <div class="jn-bottom-bar"> <p> <span class="jn-footer-copyright">© 2024 American Medical Association. <span class="inline-block">All rights reserved,</span> including those for text and data mining, AI training, <span class="inline-block">and similar technologies.</span></span> <span class="inline-block"><a href="https://www.ama-assn.org/about/terms-use" rel="nofollow" class="p0">Terms of Use</a><span class="jn-footer-pipe">|</span></span> <span class="inline-block"><a href="https://www.ama-assn.org/about/privacy-policy" rel="nofollow" class="p0">Privacy Policy</a><span class="jn-footer-pipe">|</span></span> <span class="inline-block"><a href="https://www.ama-assn.org/about/accessibility-statement" rel="nofollow" class="p0">Accessibility Statement</a><span class="jn-footer-pipe">|</span></span> <span class="inline-block"><a onclick="OneTrust.ToggleInfoDisplay()" rel="nofollow" class="p0" id="CookieFooter">Cookie Settings</a></span> </p> </div>  <a class="footer-bar-sis no-mw relative nudge-down" href="https://www.silverchair.com" target="_blank"><img class="footer-bar-sis-img mt05 mw-100" width="600" height="70" src="//cdn.jamanetwork.com/UI/app/img/powered.png" alt="Silverchair Logo" /></a> </div> </footer> </div> <div class="ss-ui-only"> <div class="widget-SelfServeContent widget-instance-AMA_SS_UI_Only"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SsUiOnly" /> <input type="hidden" class="SelfServeVersionId" value="0" /> . </div> </div> </div> </section> <div id="revealModal" class="reveal-modal" data-reveal> <div id="revealContent"></div> <a class="close-reveal-modal icon-close"></a> </div> <div class="artmet-modal" id="MetricsModal"> <div class="artmet-modal-contents"> <a class="artmet-close-modal">×</a> </div> </div> <div class="widget-SigninModals widget-instance-AMA_SigninModals"> <div class="js-modal-no-access-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Access your subscriptions</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_NoAccess_AdvancedSeamlessAccessButton"> <div class="seamless-access-button--wrap"> <button class="d-flex sa-button align-items-center" role="button" type="button"> <div class="sa-button-logo-wrap"> <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" /> </div> <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate"> <div class="sa-button-text-primary text-truncate">Access through your institution</div> </div> </button> <div class="sa-access-text text-truncate hide"> <div class="sa-cta-access"><span>Add or change institution</span></div> </div> </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_PurchaseOptions_NoAccessAndPaidPDF"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Purchase access</div> <hr> <button class="modal--btn js-btn-subscribe-journal" type="button" role="button"> <div class="text-truncate">Subscribe to journal</div> </button> <div class="modal--btn-desc">Get full journal access for 1 year</div> <button class="modal--btn js-btn-purchase-article" type="button" role="button"> <div class="text-truncate">Buy article</div> </button> <div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br> <em>Sign in or create a free account</em></div>  </div> </div> <div class="widget-DeepDyve widget-instance-AMA_NoAccess_DeepDyve"> <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jamanetworkopen.2019.20833&fieldName=journal_doi&affiliateId=JAMA" data-doi="10.1001/jamanetworkopen.2019.20833" data-fieldname="journal_doi" data-issneissn="2574-3805" data-affiliate="JAMA">Rent article</button> <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-paid-pdf-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Access your subscriptions</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_PaidPdf_AdvancedSeamlessAccessButton"> <div class="seamless-access-button--wrap"> <button class="d-flex sa-button align-items-center" role="button" type="button"> <div class="sa-button-logo-wrap"> <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" /> </div> <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate"> <div class="sa-button-text-primary text-truncate">Access through your institution</div> </div> </button> <div class="sa-access-text text-truncate hide"> <div class="sa-cta-access"><span>Add or change institution</span></div> </div> </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_PurchaseOptions_NoAccessAndPaidPDF"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Purchase access</div> <hr> <button class="modal--btn js-btn-subscribe-journal" type="button" role="button"> <div class="text-truncate">Subscribe to journal</div> </button> <div class="modal--btn-desc">Get full journal access for 1 year</div> <button class="modal--btn js-btn-purchase-article" type="button" role="button"> <div class="text-truncate">Buy article</div> </button> <div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)—<br> <em>Sign in or create a free account</em></div>  </div> </div> <div class="widget-DeepDyve widget-instance-AMA_PaidPDF_DeepDyve"> <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jamanetworkopen.2019.20833&fieldName=journal_doi&affiliateId=JAMA" data-doi="10.1001/jamanetworkopen.2019.20833" data-fieldname="journal_doi" data-issneissn="2574-3805" data-affiliate="JAMA">Rent article</button> <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-free-pdf-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Sign in to access free PDF</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_FreePdf_AdvancedSeamlessAccessButton"> <div class="seamless-access-button--wrap"> <button class="d-flex sa-button align-items-center" role="button" type="button"> <div class="sa-button-logo-wrap"> <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" /> </div> <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate"> <div class="sa-button-text-primary text-truncate">Access through your institution</div> </div> </button> <div class="sa-access-text text-truncate hide"> <div class="sa-cta-access"><span>Add or change institution</span></div> </div> </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_FreePdf_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-save-search-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Save your search</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-SelfServeContent widget-instance-AMA_SaveSearch_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_SaveSearch"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_SaveSearch" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Purchase access</div> <hr /> <button class="modal--btn js-btn-subscribe-now">Subscribe now</button>  </div> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-follow-collection-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Customize your interests</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-SelfServeContent widget-instance-AMA_FollowCollection_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_FollowCollection"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_FollowCollection" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--sub-title">Create a personal account or sign in to:</div> <ul> <li>Register for email alerts with links to free full-text articles</li> <li>Access PDFs of free articles</li> <li>Manage your interests</li> <li>Save searches and receive search alerts</li> <ul>  </div> </div> <div class="modal--link-wrap"> <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="js-modal-user-comment-reveal no-access reveal-modal modal tiny" data-reveal> <div class="modal--box"> <div class="modal--title">Make a comment</div> <hr /> <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjamanetworkopen%2ffullarticle%2f2760661"> Sign in<span class="fw-normal"> | personal account</span> </button> <div class="widget-SelfServeContent widget-instance-AMA_UserComment_SigninModal_CreateAccount"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--title">Free access to newly published articles</div> <hr> <button class="modal--btn js-btn-create-personal-account" type="button" role="button"> <div class="text-truncate">Create a free personal account</div> </button> <div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>  </div> </div> <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_UserComment"> <div class="self-serve"> <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_UserComment" /> <input type="hidden" class="SelfServeVersionId" value="0" /> <div class="modal--sub-title">Create a personal account or sign in to:</div> <ul> <li>Register for email alerts with links to free full-text articles</li> <li>Access PDFs of free articles</li> <li>Manage your interests</li> <li>Save searches and receive search alerts</li> <ul>  </div> </div> <div class="modal--link-wrap"> <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a> </div> </div> <a class="close-reveal-modal icon-close"></a> </div> <div class="hidden-true js-modal-page-data" data-store-url="https://store.jamanetwork.com" data-store-purchase-url="https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com" data-store-subscribe-url="https://store.jamanetwork.com"> </div> </div> <script src="//cdn.jamanetwork.com/UI/app/vendor/jquery-2.2.4.min.js?v=638654734634555810"></script> <script>window.jQuery || document.write('<script src="/UI/app/vendor/jquery-2.2.4.min.js">\x3C/script>')</script> <script src="//cdn.jamanetwork.com/UI/app/dist/app.min.js?v=638677764559592887" defer></script> <script src="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.js" type="text/javascript"></script> <script src="//d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script defer src='//js.trendmd.com/trendmd.min.js' data-trendmdconfig='{"element":"#trendmd-suggestions"}'></script> <script type='text/javascript' src='https://platform-api.sharethis.com/js/sharethis.js#property=643701de45aa460012e1032e&product=sop' async='async'></script> <script> var App = App || {}; App.showCmePromo = false; </script> </form> <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/scss/modules/_trendMD.css"> <div class="widget-CustomJSScript widget-instance-"> <script src="//cdn.jamanetwork.com/ama/ama.proxylogging.js" async></script> </div> </body> </html>